[2025-05-13T17:13:57.806+0000] {local_task_job_runner.py:123} INFO - ::group::Pre task execution logs
[2025-05-13T17:13:57.831+0000] {taskinstance.py:2613} INFO - Dependencies all met for dep_context=non-requeueable deps ti=<TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:13:45.945547+00:00 [queued]>
[2025-05-13T17:13:57.846+0000] {taskinstance.py:2613} INFO - Dependencies all met for dep_context=requeueable deps ti=<TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:13:45.945547+00:00 [queued]>
[2025-05-13T17:13:57.847+0000] {taskinstance.py:2866} INFO - Starting attempt 1 of 1
[2025-05-13T17:13:57.867+0000] {taskinstance.py:2889} INFO - Executing <Task(PythonOperator): process_alny> on 2025-05-13 17:13:45.945547+00:00
[2025-05-13T17:13:57.885+0000] {warnings.py:112} WARNING - /home/***/.local/lib/python3.12/site-packages/***/task/task_runner/standard_task_runner.py:70: DeprecationWarning: This process (pid=1091) is multi-threaded, use of fork() may lead to deadlocks in the child.
  pid = os.fork()

[2025-05-13T17:13:57.888+0000] {standard_task_runner.py:72} INFO - Started process 1092 to run task
[2025-05-13T17:13:57.888+0000] {standard_task_runner.py:104} INFO - Running: ['***', 'tasks', 'run', 'sec_filing_scheduler', 'process_alny', 'manual__2025-05-13T17:13:45.945547+00:00', '--job-id', '99', '--raw', '--subdir', 'DAGS_FOLDER/orchestrate_clinical_pipeline.py', '--cfg-path', '/tmp/tmp18ej5k_6']
[2025-05-13T17:13:57.892+0000] {standard_task_runner.py:105} INFO - Job 99: Subtask process_alny
[2025-05-13T17:13:57.971+0000] {task_command.py:467} INFO - Running <TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:13:45.945547+00:00 [running]> on host c1a7243cf3b7
[2025-05-13T17:13:58.102+0000] {taskinstance.py:3132} INFO - Exporting env vars: AIRFLOW_CTX_DAG_OWNER='***' AIRFLOW_CTX_DAG_ID='sec_filing_scheduler' AIRFLOW_CTX_TASK_ID='process_alny' AIRFLOW_CTX_EXECUTION_DATE='2025-05-13T17:13:45.945547+00:00' AIRFLOW_CTX_TRY_NUMBER='1' AIRFLOW_CTX_DAG_RUN_ID='manual__2025-05-13T17:13:45.945547+00:00'
[2025-05-13T17:13:58.104+0000] {taskinstance.py:731} INFO - ::endgroup::
[2025-05-13T17:13:58.170+0000] {connection.py:277} WARNING - Connection schemes (type: google_cloud_platform) shall not contain '_' according to RFC3986.
[2025-05-13T17:13:58.172+0000] {base.py:84} INFO - Retrieving connection 'google_cloud_default'
[2025-05-13T17:13:59.261+0000] {logging_mixin.py:190} INFO - Found 141 8-K filings
[2025-05-13T17:13:59.261+0000] {logging_mixin.py:190} INFO - Found 13 10-K filings
[2025-05-13T17:13:59.262+0000] {logging_mixin.py:190} INFO - Found 37 10-Q filings
[2025-05-13T17:13:59.263+0000] {logging_mixin.py:190} INFO - Found 191 new filings.
[2025-05-13T17:13:59.264+0000] {logging_mixin.py:190} INFO - Processing 191 filings...
[2025-05-13T17:13:59.265+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000052
[2025-05-13T17:13:59.269+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000050
[2025-05-13T17:13:59.270+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000038
[2025-05-13T17:13:59.272+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000031
[2025-05-13T17:13:59.273+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000026
[2025-05-13T17:13:59.276+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000020
[2025-05-13T17:13:59.280+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000008
[2025-05-13T17:13:59.282+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000053
[2025-05-13T17:13:59.285+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000041
[2025-05-13T17:13:59.285+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000052
[2025-05-13T17:13:59.286+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000039
[2025-05-13T17:13:59.289+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000027
[2025-05-13T17:13:59.290+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000023
[2025-05-13T17:13:59.293+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000021
[2025-05-13T17:13:59.293+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-24-057906
[2025-05-13T17:13:59.294+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-24-000008
[2025-05-13T17:13:59.297+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-24-000253
[2025-05-13T17:13:59.300+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-24-011278
[2025-05-13T17:13:59.302+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-24-003854
[2025-05-13T17:13:59.312+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-23-000015
[2025-05-13T17:13:59.307+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-23-001622
[2025-05-13T17:13:59.308+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-253084
[2025-05-13T17:13:59.310+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-245768
[2025-05-13T17:13:59.305+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-23-000023
[2025-05-13T17:13:59.313+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-202313
[2025-05-13T17:13:59.315+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-194715
[2025-05-13T17:13:59.318+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-179631
[2025-05-13T17:13:59.321+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-151845
[2025-05-13T17:13:59.322+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-23-000011
[2025-05-13T17:13:59.325+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-23-000728
[2025-05-13T17:13:59.327+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-064580
[2025-05-13T17:13:59.328+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-23-000005
[2025-05-13T17:13:59.331+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-23-000344
[2025-05-13T17:13:59.335+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-004109
[2025-05-13T17:13:59.338+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-23-003554
[2025-05-13T17:13:59.340+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-22-000026
[2025-05-13T17:13:59.342+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-22-001411
[2025-05-13T17:13:59.343+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-246487
[2025-05-13T17:13:59.344+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-243702
[2025-05-13T17:13:59.348+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-228534
[2025-05-13T17:14:00.977+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-24-000039
[2025-05-13T17:14:01.110+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000039
[2025-05-13T17:14:01.296+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-25-000020
[2025-05-13T17:14:01.404+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:01.534+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-24-000021
[2025-05-13T17:14:01.628+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000020
[2025-05-13T17:14:01.679+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-25-000031
[2025-05-13T17:14:02.030+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000031
[2025-05-13T17:14:02.270+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:02.273+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-22-000945
[2025-05-13T17:14:01.749+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-25-000008
[2025-05-13T17:14:01.753+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-25-000038
[2025-05-13T17:14:01.778+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-25-000050
[2025-05-13T17:14:01.779+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-24-000027
[2025-05-13T17:14:01.794+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000021
[2025-05-13T17:14:01.988+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:01.687+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-22-000020
[2025-05-13T17:14:01.551+0000] {logging_mixin.py:190} INFO - No sections found in 8-K filing 0001178670-24-000052
[2025-05-13T17:14:01.720+0000] {logging_mixin.py:190} INFO - Finished 1/191: 0001178670-24-000039
[2025-05-13T17:14:02.618+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000008
[2025-05-13T17:14:02.640+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000038
[2025-05-13T17:14:02.665+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:02.699+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000050
[2025-05-13T17:14:02.838+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000027
[2025-05-13T17:14:04.156+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:02.914+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:02.990+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.032+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.140+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-173444
[2025-05-13T17:14:03.146+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.169+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.252+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.259+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.331+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.371+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.385+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.413+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000052
[2025-05-13T17:14:06.353+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:03.596+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.649+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.716+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:03.766+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:03.672+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:07.495+0000] {logging_mixin.py:190} INFO - Finished 2/191: 0001178670-25-000031
[2025-05-13T17:14:04.059+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:02.851+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:14:08.135+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-077831
[2025-05-13T17:14:04.830+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:05.307+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:05.487+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:05.530+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:03.425+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:06.609+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-22-000016
[2025-05-13T17:14:06.847+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-03-08_0001193125-23-064580.txt
[2025-05-13T17:14:06.975+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-05-04_0001157523-23-000728.txt
[2025-05-13T17:14:07.065+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-02-23_0001157523-23-000344.txt
[2025-05-13T17:14:07.071+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2024/ALNY_8-K_2024-01-19_0001193125-24-011278.txt
[2025-05-13T17:14:07.133+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-22-000494
[2025-05-13T17:14:07.284+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-096176
[2025-05-13T17:14:07.374+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-09-13_0001193125-22-243702.txt
[2025-05-13T17:14:03.844+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:07.812+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-094409
[2025-05-13T17:14:07.922+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2024/ALNY_8-K_2024-03-04_0001193125-24-057906.txt
[2025-05-13T17:14:08.059+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:08.029+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-09-28_0001193125-23-245768.txt
[2025-05-13T17:14:04.337+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-157503
[2025-05-13T17:14:08.329+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-08-03_0001193125-23-202313.txt
[2025-05-13T17:14:08.421+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-01-06_0001193125-23-003554.txt
[2025-05-13T17:14:08.438+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-10-27_0001157523-22-001411.txt
[2025-05-13T17:14:08.766+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-08-24_0001193125-22-228534.txt
[2025-05-13T17:14:09.252+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-09-16_0001193125-22-246487.txt
[2025-05-13T17:14:09.914+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:10.403+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:10.526+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:10.549+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-11-02_0001157523-23-001622.txt
[2025-05-13T17:14:10.611+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-06-30_0001193125-23-179631.txt
[2025-05-13T17:14:10.623+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:10.672+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-10-10_0001193125-23-253084.txt
[2025-05-13T17:14:10.940+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-07-28_0001157523-22-000945.txt
[2025-05-13T17:14:11.368+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-07-26_0001193125-23-194715.txt
[2025-05-13T17:14:11.528+0000] {logging_mixin.py:190} INFO - Finished 3/191: 0001178670-25-000020
[2025-05-13T17:14:11.911+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-23-000344
[2025-05-13T17:14:12.110+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2024/ALNY_8-K_2024-02-15_0001157523-24-000253.txt
[2025-05-13T17:14:12.207+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-064580
[2025-05-13T17:14:12.319+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-23-000728
[2025-05-13T17:14:12.906+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-24-011278
[2025-05-13T17:14:13.394+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-243702
[2025-05-13T17:14:16.519+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:13.447+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-05-23_0001193125-23-151845.txt
[2025-05-13T17:14:13.484+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-24-057906
[2025-05-13T17:14:16.831+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:17.045+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-22-000175
[2025-05-13T17:14:15.137+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-003554
[2025-05-13T17:14:15.338+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:15.438+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:15.599+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:15.601+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-228534
[2025-05-13T17:14:16.007+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-22-001411
[2025-05-13T17:14:16.042+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-246487
[2025-05-13T17:14:16.092+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:15.529+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:16.114+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-03-17_0001193125-22-077831.txt
[2025-05-13T17:14:16.156+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:16.214+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:16.451+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:19.795+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-21-000028
[2025-05-13T17:14:16.629+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-22-000013
[2025-05-13T17:14:13.534+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:16.833+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-179631
[2025-05-13T17:14:16.941+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-23-001622
[2025-05-13T17:14:13.927+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-245768
[2025-05-13T17:14:17.067+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-22-000945
[2025-05-13T17:14:21.227+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:21.465+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-310422
[2025-05-13T17:14:17.287+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:21.644+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-267358
[2025-05-13T17:14:17.331+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2024/ALNY_8-K_2024-01-08_0001193125-24-003854.txt
[2025-05-13T17:14:17.680+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-005024
[2025-05-13T17:14:17.932+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:17.959+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:18.027+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:22.963+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-169325
[2025-05-13T17:14:18.452+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-253084
[2025-05-13T17:14:23.068+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin', 'indication': 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'FILING DATE: 2023-10-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:19.222+0000] {logging_mixin.py:190} INFO - Finished 4/191: 0001178670-24-000027
[2025-05-13T17:14:19.362+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-22-001706
[2025-05-13T17:14:19.581+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-362387
[2025-05-13T17:14:19.582+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-151845
[2025-05-13T17:14:13.443+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-202313
[2025-05-13T17:14:24.734+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:20.216+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-04-05_0001193125-22-096176.txt
[2025-05-13T17:14:20.535+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Item 8.01', 'Filing date: 2023-06-30', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:20.570+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:20.630+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-04-04_0001193125-22-094409.txt
[2025-05-13T17:14:20.777+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:17.091+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-06-14_0001193125-22-173444.txt
[2025-05-13T17:14:17.269+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-194715
[2025-05-13T17:14:17.297+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2023/ALNY_8-K_2023-01-09_0001193125-23-004109.txt
[2025-05-13T17:14:22.197+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-077831
[2025-05-13T17:14:22.494+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-04-28_0001157523-22-000494.txt
[2025-05-13T17:14:22.797+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-21-000024
[2025-05-13T17:14:22.904+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-234071
[2025-05-13T17:14:18.112+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-24-000253
[2025-05-13T17:14:18.918+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:23.124+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-21-000017
[2025-05-13T17:14:23.745+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:23.911+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:24.441+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:20.214+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-05-23_0001193125-22-157503.txt
[2025-05-13T17:14:24.777+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:24.893+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-21-000536
[2025-05-13T17:14:24.919+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-24-003854
[2025-05-13T17:14:25.251+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-113304
[2025-05-13T17:14:25.371+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:25.453+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-21-000010
[2025-05-13T17:14:25.939+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-21-000169
[2025-05-13T17:14:26.345+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'zilebesiran', 'mechanism_of_action': 'siRNA therapeutic targeting liver-expressed angiotensinogen', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Item 1.01', 'Filing Date: 2023-07-26', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:26.487+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:26.610+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:26.745+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:27.194+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:27.225+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:27.354+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-096176
[2025-05-13T17:14:27.610+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-094409
[2025-05-13T17:14:27.939+0000] {logging_mixin.py:190} INFO - Finished 5/191: 0001178670-24-000052
[2025-05-13T17:14:28.147+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-21-005849
[2025-05-13T17:14:28.201+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:28.501+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-23-004109
[2025-05-13T17:14:28.701+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-173444
[2025-05-13T17:14:28.708+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:28.805+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:28.963+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:29.603+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-02-10_0001157523-22-000175.txt
[2025-05-13T17:14:29.625+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-22-000494
[2025-05-13T17:14:29.870+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-20-000019
[2025-05-13T17:14:30.007+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-10-28_0001193125-21-310422.txt
[2025-05-13T17:14:30.127+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-20-001446
[2025-05-13T17:14:30.717+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:30.807+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-157503
[2025-05-13T17:14:30.983+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-262507
[2025-05-13T17:14:31.062+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:31.330+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-09-08_0001193125-21-267358.txt
[2025-05-13T17:14:31.341+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-01-10_0001193125-22-005024.txt
[2025-05-13T17:14:31.091+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Item 8.01', 'Filing Date: 2022-04-04', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:31.486+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:31.507+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:31.624+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:31.767+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.152000 seconds
[2025-05-13T17:14:31.906+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:31.926+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:32.037+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin', 'indication': 'polyneuropathy of hereditary transthyretin-mediated amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2022-06-14', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm'], 'aliases': ['vutrisiran']}]}
[2025-05-13T17:14:32.309+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-225661
[2025-05-13T17:14:32.376+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-05-21_0001193125-21-169325.txt
[2025-05-13T17:14:32.483+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.022000 seconds
[2025-05-13T17:14:32.526+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:32.565+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-12-20_0001193125-21-362387.txt
[2025-05-13T17:14:32.759+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2022/ALNY_8-K_2022-01-04_0001193125-22-001706.txt
[2025-05-13T17:14:33.128+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:33.340+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-20-000015
[2025-05-13T17:14:33.581+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:33.582+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-20-001145
[2025-05-13T17:14:33.718+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.306000 seconds
[2025-05-13T17:14:33.886+0000] {logging_mixin.py:190} INFO - Finished 6/191: 0001178670-25-000008
[2025-05-13T17:14:33.941+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.966000 seconds
[2025-05-13T17:14:34.238+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:34.398+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-139137
[2025-05-13T17:14:34.453+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-20-000007
[2025-05-13T17:14:34.473+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-22-000175
[2025-05-13T17:14:34.617+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-08-03_0001193125-21-234071.txt
[2025-05-13T17:14:34.654+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-310422
[2025-05-13T17:14:34.782+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-20-000673
[2025-05-13T17:14:35.144+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-04-29_0001157523-21-000536.txt
[2025-05-13T17:14:35.152+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:35.362+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-105270
[2025-05-13T17:14:35.595+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-005024
[2025-05-13T17:14:35.664+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-267358
[2025-05-13T17:14:35.944+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:36.288+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.254000 seconds
[2025-05-13T17:14:37.160+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:37.300+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-02-11_0001157523-21-000169.txt
[2025-05-13T17:14:37.318+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:37.620+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:37.709+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:37.742+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-169325
[2025-05-13T17:14:37.939+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-04-12_0001193125-21-113304.txt
[2025-05-13T17:14:37.844+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:38.031+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-22-001706
[2025-05-13T17:14:38.604+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:38.610+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:38.483+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:38.755+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-362387
[2025-05-13T17:14:38.756+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:39.422+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:39.441+0000] {logging_mixin.py:190} INFO - Finished 7/191: 0001178670-25-000038
[2025-05-13T17:14:39.495+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:39.700+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:39.872+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-234071
[2025-05-13T17:14:39.744+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:39.928+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-099010
[2025-05-13T17:14:39.983+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-052682
[2025-05-13T17:14:40.321+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:42.956+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-20-005791
[2025-05-13T17:14:40.644+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-11-05_0001157523-20-001446.txt
[2025-05-13T17:14:40.987+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:43.256+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.846000 seconds
[2025-05-13T17:14:41.106+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:41.114+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-21-000536
[2025-05-13T17:14:41.131+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-20-000004
[2025-05-13T17:14:41.427+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:41.529+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-20-000164
[2025-05-13T17:14:41.549+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:41.701+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-113304
[2025-05-13T17:14:41.702+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:41.775+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-10-02_0001193125-20-262507.txt
[2025-05-13T17:14:41.932+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-21-000169
[2025-05-13T17:14:42.052+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:42.571+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:42.596+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:42.866+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-08-06_0001157523-20-001145.txt
[2025-05-13T17:14:40.601+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:43.190+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2021/ALNY_8-K_2021-01-11_0001193125-21-005849.txt
[2025-05-13T17:14:41.005+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:43.681+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-05-11_0001193125-20-139137.txt
[2025-05-13T17:14:43.841+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:43.980+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-05-06_0001157523-20-000673.txt
[2025-05-13T17:14:44.305+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:44.319+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-296636
[2025-05-13T17:14:44.714+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2021-04-12', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm'], 'aliases': ['patisiran']}]}
[2025-05-13T17:14:44.888+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-20-001446
[2025-05-13T17:14:44.979+0000] {logging_mixin.py:190} INFO - Finished 8/191: 0001178670-25-000050
[2025-05-13T17:14:45.043+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:45.230+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-08-20_0001193125-20-225661.txt
[2025-05-13T17:14:45.427+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-19-000005
[2025-05-13T17:14:45.718+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:45.802+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:45.928+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:45.939+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:46.005+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-19-002155
[2025-05-13T17:14:46.166+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:46.168+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.779000 seconds
[2025-05-13T17:14:46.273+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:46.290+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-261686
[2025-05-13T17:14:46.610+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2024/ALNY_10-Q_2024-10-31_0001178670-24-000053.txt
[2025-05-13T17:14:46.764+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-19-029367
[2025-05-13T17:14:46.797+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:50.183+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-192410
[2025-05-13T17:14:47.169+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2024/ALNY_10-Q_2024-08-01_0001178670-24-000041.txt
[2025-05-13T17:14:47.195+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:47.325+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-19-001714
[2025-05-13T17:14:47.326+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-262507
[2025-05-13T17:14:47.502+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-20-001145
[2025-05-13T17:14:47.675+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-21-005849
[2025-05-13T17:14:47.902+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.273000 seconds
[2025-05-13T17:14:47.931+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.236000 seconds
[2025-05-13T17:14:47.938+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-02-27_0001193125-20-052682.txt
[2025-05-13T17:14:47.988+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.435000 seconds
[2025-05-13T17:14:48.154+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2024/ALNY_10-Q_2024-05-02_0001178670-24-000023.txt
[2025-05-13T17:14:48.165+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-20-000673
[2025-05-13T17:14:48.237+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-139137
[2025-05-13T17:14:48.805+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.177000 seconds
[2025-05-13T17:14:48.870+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:49.223+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.439553 seconds
[2025-05-13T17:14:49.921+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:50.176+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-225661
[2025-05-13T17:14:47.118+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:50.419+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:50.783+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 4.974000 seconds
[2025-05-13T17:14:51.064+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:51.087+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:51.075+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:51.154+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:53.952+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-19-015366
[2025-05-13T17:14:51.471+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:54.138+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 1.618000 seconds
[2025-05-13T17:14:51.734+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2025/ALNY_10-Q_2025-05-01_0001178670-25-000052.txt
[2025-05-13T17:14:51.964+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:52.128+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:52.296+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:52.398+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:52.470+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000053
[2025-05-13T17:14:54.714+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:14:52.624+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:52.771+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.527000 seconds
[2025-05-13T17:14:52.812+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, {'name': 'ALN-AGT', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:55.429+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-19-003022
[2025-05-13T17:14:53.221+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:53.241+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-052682
[2025-05-13T17:14:53.456+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:56.372+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.748000 seconds
[2025-05-13T17:14:53.811+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-152751
[2025-05-13T17:14:51.347+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}]}
[2025-05-13T17:14:56.568+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-19-000264
[2025-05-13T17:14:54.625+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-01-13_0001193125-20-005791.txt
[2025-05-13T17:14:54.626+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-19-001001
[2025-05-13T17:14:54.652+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-122475
[2025-05-13T17:14:52.605+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000041
[2025-05-13T17:14:54.869+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-101737
[2025-05-13T17:14:55.295+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-10-31_0001157523-19-002155.txt
[2025-05-13T17:14:55.316+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-11-20_0001193125-19-296636.txt
[2025-05-13T17:14:53.200+0000] {logging_mixin.py:190} INFO - Finished 9/191: 0001178670-24-000021
[2025-05-13T17:14:55.903+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-04-13_0001193125-20-105270.txt
[2025-05-13T17:14:55.926+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:14:56.362+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000052
[2025-05-13T17:14:53.759+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000023
[2025-05-13T17:14:59.306+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic targeting TTR', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': 'RNAi therapeutic targeting TTR', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3, investigating cardiac manifestations, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic targeting antithrombin', 'target': 'antithrombin', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic targeting LPHN1', 'target': 'LPHN1', 'indication': 'primary hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}]}
[2025-05-13T17:14:59.614+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-003205
[2025-05-13T17:14:57.089+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3, positive topline results reported'], 'upcoming_milestones': ['Regulatory approval for broader indication'], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}]}
[2025-05-13T17:14:59.696+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-346287
[2025-05-13T17:14:57.334+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:00.055+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.101000 seconds
[2025-05-13T17:14:57.945+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-07-11_0001193125-19-192410.txt
[2025-05-13T17:14:58.347+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:58.089+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-04-06_0001193125-20-099010.txt
[2025-05-13T17:14:58.294+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:14:58.504+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-19-009888
[2025-05-13T17:14:58.521+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Alzheimer’s Disease', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nucresiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inotersen', 'mechanism_of_action': 'antisense drug', 'target': 'specific genes', 'indication': 'adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'WAINUA', 'mechanism_of_action': 'antisense drug', 'target': 'specific genes', 'indication': 'not specified', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}]}
[2025-05-13T17:15:02.158+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-18-028070
[2025-05-13T17:14:59.120+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:59.121+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:51.552+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2020/ALNY_8-K_2020-02-06_0001157523-20-000164.txt
[2025-05-13T17:14:59.312+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:14:59.354+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:02.942+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 188358, Requested 50840. Please try again in 11.759s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:14:57.251+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:14:59.781+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-005791
[2025-05-13T17:14:57.598+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:00.624+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:04.390+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 183475, Requested 50825. Please try again in 10.29s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:04.515+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:01.129+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 188144, Requested 50850. Please try again in 11.698s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:04.793+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:01.225+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:01.463+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-296636
[2025-05-13T17:15:01.667+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:01.766+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-19-002155
[2025-05-13T17:15:01.813+0000] {logging_mixin.py:190} INFO - Finished 10/191: 0001193125-22-243702
[2025-05-13T17:15:01.986+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-105270
[2025-05-13T17:14:59.119+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-08-06_0001157523-19-001714.txt
[2025-05-13T17:14:56.806+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-10-03_0001193125-19-261686.txt
[2025-05-13T17:15:02.980+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-192410
[2025-05-13T17:15:03.019+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:03.694+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.152000 seconds
[2025-05-13T17:15:04.189+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'FILING DATE: 2020-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'FILING DATE: 2020-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:04.230+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 189046, Requested 51219. Please try again in 12.079s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:04.269+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-20-099010
[2025-05-13T17:15:00.665+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:04.456+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:01.125+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:04.698+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:01.222+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:05.005+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 181457, Requested 51181. Please try again in 9.791s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:05.011+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': 'acute hepatic porphyria (AHP)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', '2019-11-20', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm'], 'aliases': ['givosiran']}]}
[2025-05-13T17:15:05.141+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:05.216+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-05-01_0001157523-19-001001.txt
[2025-05-13T17:15:05.242+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:05.249+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:05.279+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-20-000164
[2025-05-13T17:15:05.349+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-05-21_0001193125-19-152751.txt
[2025-05-13T17:15:05.367+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:05.724+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:05.749+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:05.976+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:06.261+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-18-002349
[2025-05-13T17:15:06.338+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:06.461+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'lumasiran', 'mechanism_of_action': 'RNA interference targeting glycolate oxidase', 'target': 'glycolate oxidase', 'indication': 'primary hyperoxaluria type 1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, {'name': 'ALN-AAT02', 'mechanism_of_action': 'RNA interference', 'target': '', 'indication': 'alpha-1 antitrypsin deficiency-associated liver disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Item 8.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, {'name': 'DCR-A1AT', 'mechanism_of_action': 'RNA interference', 'target': '', 'indication': 'alpha-1 antitrypsin deficiency-associated liver disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:06.607+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-02-07_0001157523-19-000264.txt
[2025-05-13T17:15:06.617+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.359000 seconds
[2025-05-13T17:15:07.024+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 180400, Requested 50840. Please try again in 9.372s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:11.374+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:07.515+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:07.688+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:07.874+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-261686
[2025-05-13T17:15:07.924+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:08.659+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-19-001714
[2025-05-13T17:15:08.671+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-296858
[2025-05-13T17:15:08.857+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-290906
[2025-05-13T17:15:08.888+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-04-26_0001193125-19-122475.txt
[2025-05-13T17:15:09.018+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:09.552+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:09.621+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:09.989+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-251725
[2025-05-13T17:15:10.042+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:10.107+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-245969
[2025-05-13T17:15:10.281+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.567000 seconds
[2025-05-13T17:15:10.356+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.990000 seconds
[2025-05-13T17:15:10.646+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-01-07_0001193125-19-003205.txt
[2025-05-13T17:15:10.702+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:10.843+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-18-018696
[2025-05-13T17:15:11.091+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-19-001001
[2025-05-13T17:15:07.322+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 180537, Requested 51092. Please try again in 9.488s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:11.611+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-152751
[2025-05-13T17:15:11.663+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:12.017+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 4.984000 seconds
[2025-05-13T17:15:12.090+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:12.324+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-01-15_0001193125-19-009888.txt
[2025-05-13T17:15:12.397+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:12.445+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:12.815+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.518000 seconds
[2025-05-13T17:15:12.844+0000] {logging_mixin.py:190} INFO - Finished 11/191: 0001193125-24-057906
[2025-05-13T17:15:12.892+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:12.934+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-18-001671
[2025-05-13T17:15:13.119+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2019/ALNY_8-K_2019-04-09_0001193125-19-101737.txt
[2025-05-13T17:15:13.301+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-19-000264
[2025-05-13T17:15:13.497+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:13.792+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.964000 seconds
[2025-05-13T17:15:14.078+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:14.131+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:14.254+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:14.254+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:14.374+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:14.479+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:14.556+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:14.683+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-164173
[2025-05-13T17:15:14.937+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.859000 seconds
[2025-05-13T17:15:15.200+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-18-011031
[2025-05-13T17:15:15.238+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-122475
[2025-05-13T17:15:15.294+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-003205
[2025-05-13T17:15:15.457+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:15.529+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 191114, Requested 50818. Please try again in 12.579s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:15.932+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:16.130+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:16.173+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.800000 seconds
[2025-05-13T17:15:16.613+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-18-000981
[2025-05-13T17:15:16.846+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-009888
[2025-05-13T17:15:17.041+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-125102
[2025-05-13T17:15:17.240+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.454000 seconds
[2025-05-13T17:15:17.239+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:17.333+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:17.710+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-19-101737
[2025-05-13T17:15:17.724+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:17.583+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:17.953+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:18.013+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2019-01-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:18.053+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:18.158+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:18.242+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:18.285+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:18.430+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:18.430+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-10-02_0001193125-18-290906.txt
[2025-05-13T17:15:18.465+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-106272
[2025-05-13T17:15:18.581+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-11-07_0001157523-18-002349.txt
[2025-05-13T17:15:18.941+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:18.949+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:18.976+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-10-10_0001193125-18-296858.txt
[2025-05-13T17:15:19.075+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.599000 seconds
[2025-05-13T17:15:19.183+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:19.183+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Item 1.01', 'Filing Date: 2019-04-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2019-04-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}]}
[2025-05-13T17:15:19.252+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.133000 seconds
[2025-05-13T17:15:19.279+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2023/ALNY_10-Q_2023-08-03_0001178670-23-000015.txt
[2025-05-13T17:15:19.407+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.225000 seconds
[2025-05-13T17:15:19.528+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-082339
[2025-05-13T17:15:19.591+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-18-002152
[2025-05-13T17:15:19.598+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:19.833+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.883000 seconds
[2025-05-13T17:15:19.871+0000] {logging_mixin.py:190} INFO - Finished 12/191: 0001157523-23-000344
[2025-05-13T17:15:19.952+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.547000 seconds
[2025-05-13T17:15:20.004+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-08-17_0001193125-18-251725.txt
[2025-05-13T17:15:20.216+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:20.200+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:20.126+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:20.237+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:20.436+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-18-000252
[2025-05-13T17:15:20.488+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:20.501+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:20.540+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-08-10_0001193125-18-245969.txt
[2025-05-13T17:15:20.671+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:20.693+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.345000 seconds
[2025-05-13T17:15:20.742+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-005021
[2025-05-13T17:15:21.003+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.948000 seconds
[2025-05-13T17:15:21.107+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:21.153+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-08-02_0001157523-18-001671.txt
[2025-05-13T17:15:21.242+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:21.256+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:21.524+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.402000 seconds
[2025-05-13T17:15:21.525+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-290906
[2025-05-13T17:15:21.641+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-05-15_0001193125-18-164173.txt
[2025-05-13T17:15:21.642+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-296858
[2025-05-13T17:15:23.954+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:21.929+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-23-000015
[2025-05-13T17:15:22.029+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.088000 seconds
[2025-05-13T17:15:22.042+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-18-002349
[2025-05-13T17:15:21.948+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:22.116+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.118000 seconds
[2025-05-13T17:15:22.265+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.428000 seconds
[2025-05-13T17:15:22.266+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:22.826+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-251725
[2025-05-13T17:15:22.947+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.427000 seconds
[2025-05-13T17:15:22.997+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-04-20_0001193125-18-125102.txt
[2025-05-13T17:15:23.158+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.918000 seconds
[2025-05-13T17:15:23.178+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:23.781+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:25.080+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-342673
[2025-05-13T17:15:23.838+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:23.850+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:23.851+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-05-03_0001157523-18-000981.txt
[2025-05-13T17:15:21.655+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:23.961+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-18-001686
[2025-05-13T17:15:24.076+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:24.252+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:24.325+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.324000 seconds
[2025-05-13T17:15:24.326+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:24.341+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-245969
[2025-05-13T17:15:24.551+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:24.737+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-18-001671
[2025-05-13T17:15:24.928+0000] {logging_mixin.py:190} INFO - Finished 13/191: 0001193125-23-064580
[2025-05-13T17:15:23.788+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-12-10_0001193125-18-346287.txt
[2025-05-13T17:15:25.126+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-164173
[2025-05-13T17:15:25.357+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-17-022281
[2025-05-13T17:15:25.322+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:25.433+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-17-003038
[2025-05-13T17:15:25.685+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-08-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:26.226+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-17-016993
[2025-05-13T17:15:25.743+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-278495
[2025-05-13T17:15:25.972+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:26.270+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:26.119+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-125102
[2025-05-13T17:15:25.809+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:26.288+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-17-002334
[2025-05-13T17:15:26.032+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:26.297+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-195385
[2025-05-13T17:15:26.286+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:26.228+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.098000 seconds
[2025-05-13T17:15:26.284+0000] {logging_mixin.py:190} INFO - Finished 14/191: 0001157523-23-000728
[2025-05-13T17:15:26.430+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-04-03_0001193125-18-106272.txt
[2025-05-13T17:15:26.430+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-182644
[2025-05-13T17:15:26.479+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:26.540+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:26.585+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-02-08_0001157523-18-000252.txt
[2025-05-13T17:15:26.742+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-18-000981
[2025-05-13T17:15:26.806+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:27.027+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2023/ALNY_10-Q_2023-11-02_0001178670-23-000023.txt
[2025-05-13T17:15:27.085+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:27.148+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-03-14_0001193125-18-082339.txt
[2025-05-13T17:15:27.205+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2021/ALNY_10-Q_2021-10-28_0001178670-21-000028.txt
[2025-05-13T17:15:27.261+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-163465
[2025-05-13T17:15:27.262+0000] {logging_mixin.py:190} INFO - Finished 15/191: 0001193125-24-011278
[2025-05-13T17:15:27.413+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-346287
[2025-05-13T17:15:27.805+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:27.869+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:27.961+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:27.949+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'ALN-HBV02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'ALN-AAT02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:28.432+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-17-008948
[2025-05-13T17:15:28.042+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:28.059+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:28.271+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:28.352+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-106272
[2025-05-13T17:15:28.041+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:28.484+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:28.579+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:28.916+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:28.968+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-11-14_0001193125-17-342673.txt
[2025-05-13T17:15:28.975+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-18-000252
[2025-05-13T17:15:28.982+0000] {logging_mixin.py:190} INFO - Finished 16/191: 0001157523-22-000945
[2025-05-13T17:15:29.729+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:29.102+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-21-000028
[2025-05-13T17:15:29.174+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'FILING DATE: 2018-04-03', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:30.076+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-17-001455
[2025-05-13T17:15:29.426+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.270000 seconds
[2025-05-13T17:15:29.658+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-01-03_0001193125-18-001686.txt
[2025-05-13T17:15:29.703+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-23-000023
[2025-05-13T17:15:29.715+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:28.995+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.591000 seconds
[2025-05-13T17:15:29.731+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.910000 seconds
[2025-05-13T17:15:29.749+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': 'Investigational RNAi therapeutic', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['HELIOS-A Phase 3 study, positive topline results, January 2021', 'NDA submitted to FDA in April 2021, accepted by FDA', 'FDA action date set for April 14, 2022', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Submitted MAA in EU with EMA in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'AHP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'Investigational RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Hemophilia', 'preclinical_data': [], 'clinical_trials': ['Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'Potential filing date moved to 2024'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Atypical hemolytic uremic syndrome', 'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:29.774+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:29.881+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-08-09_0001157523-17-002334.txt
[2025-05-13T17:15:29.207+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:30.153+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-082339
[2025-05-13T17:15:30.208+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:30.235+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:30.399+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:30.501+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-05-25_0001193125-17-182644.txt
[2025-05-13T17:15:30.534+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'eplontersen', 'mechanism_of_action': '', 'target': '', 'indication': 'polyneuropathy of hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'acoramidis', 'mechanism_of_action': 'TTR stabilizer', 'target': 'TTR', 'indication': 'ATTR-CM', 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'once-monthly subcutaneous RNAi therapy', 'target': '', 'indication': 'primary hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, {'name': 'inotersen', 'mechanism_of_action': 'antisense drug', 'target': '', 'indication': 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}]}
[2025-05-13T17:15:32.941+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-17-000876
[2025-05-13T17:15:30.706+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:33.354+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.262000 seconds
[2025-05-13T17:15:33.427+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:33.850+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.461000 seconds
[2025-05-13T17:15:31.312+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-06-06_0001193125-17-195385.txt
[2025-05-13T17:15:31.330+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:31.869+0000] {logging_mixin.py:190} INFO - Finished 17/191: 0001193125-23-003554
[2025-05-13T17:15:31.942+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-11-07_0001157523-17-003038.txt
[2025-05-13T17:15:32.287+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:32.290+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 187755, Requested 45426. Please try again in 9.954s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:32.404+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 187457, Requested 50822. Please try again in 11.483s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:34.671+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:32.523+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.386000 seconds
[2025-05-13T17:15:32.525+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:35.063+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.797000 seconds
[2025-05-13T17:15:30.571+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:32.956+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-342673
[2025-05-13T17:15:35.407+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:35.698+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-16-007200
[2025-05-13T17:15:30.724+0000] {logging_mixin.py:190} INFO - Processing filing: 0001564590-17-001649
[2025-05-13T17:15:33.229+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:33.429+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:36.138+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 177585, Requested 51256. Please try again in 8.652s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:33.705+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:36.369+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 176181, Requested 51195. Please try again in 8.212s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:36.440+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:34.292+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:34.298+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:34.459+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.525000 seconds
[2025-05-13T17:15:34.582+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:34.627+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-17-002334
[2025-05-13T17:15:34.644+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:32.455+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:37.249+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.471000 seconds
[2025-05-13T17:15:32.764+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:35.237+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-182644
[2025-05-13T17:15:37.443+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:37.527+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-731590
[2025-05-13T17:15:33.057+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Connection error.
[2025-05-13T17:15:37.663+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:30.835+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:36.262+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:36.359+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-195385
[2025-05-13T17:15:30.897+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-17-000400
[2025-05-13T17:15:34.148+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-758802
[2025-05-13T17:15:36.517+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-17-003038
[2025-05-13T17:15:36.644+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-05-09_0001193125-17-163465.txt
[2025-05-13T17:15:36.730+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:36.791+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:37.098+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:35.037+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:37.396+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:37.398+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:35.296+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 186952, Requested 50820. Please try again in 11.331s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:39.890+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:35.935+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 178660, Requested 50830. Please try again in 8.847s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:40.064+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:38.129+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:38.255+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:40.287+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-671945
[2025-05-13T17:15:38.843+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-09-07_0001193125-17-278495.txt
[2025-05-13T17:15:38.856+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2022/ALNY_10-Q_2022-10-27_0001178670-22-000026.txt
[2025-05-13T17:15:38.960+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:40.900+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-16-006448
[2025-05-13T17:15:39.540+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-713525
[2025-05-13T17:15:39.554+0000] {logging_mixin.py:190} INFO - Finished 18/191: 0001193125-22-228534
[2025-05-13T17:15:41.231+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:41.248+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:33.027+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-001686
[2025-05-13T17:15:41.413+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:41.431+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-622502
[2025-05-13T17:15:40.188+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:38.623+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-05-05_0001157523-17-001455.txt
[2025-05-13T17:15:40.314+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.859000 seconds
[2025-05-13T17:15:39.337+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2018/ALNY_8-K_2018-01-08_0001193125-18-005021.txt
[2025-05-13T17:15:40.931+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:41.147+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-01-03_0001193125-17-000876.txt
[2025-05-13T17:15:41.204+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:39.608+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:41.247+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-163465
[2025-05-13T17:15:39.788+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.337000 seconds
[2025-05-13T17:15:41.325+0000] {logging_mixin.py:190} INFO - Finished 19/191: 0001193125-22-246487
[2025-05-13T17:15:41.282+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:39.969+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Connection error.
[2025-05-13T17:15:42.676+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:41.551+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.460000 seconds
[2025-05-13T17:15:41.600+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:41.690+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2021/ALNY_10-Q_2021-04-29_0001178670-21-000017.txt
[2025-05-13T17:15:41.940+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-11-02_0001157523-16-007200.txt
[2025-05-13T17:15:42.018+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.908000 seconds
[2025-05-13T17:15:42.061+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 194526, Requested 40209. Please try again in 10.42s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:42.148+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:42.297+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:42.311+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:42.340+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:42.594+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.309000 seconds
[2025-05-13T17:15:42.671+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-22-000026
[2025-05-13T17:15:37.893+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.958000 seconds
[2025-05-13T17:15:43.171+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:43.363+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-17-001455
[2025-05-13T17:15:43.592+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-278495
[2025-05-13T17:15:43.619+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:43.722+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:43.723+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-18-005021
[2025-05-13T17:15:43.724+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:44.198+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2017/ALNY_8-K_2017-02-08_0001157523-17-000400.txt
[2025-05-13T17:15:44.200+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:44.285+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:44.384+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-582064
[2025-05-13T17:15:44.514+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.359000 seconds
[2025-05-13T17:15:44.477+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:44.566+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-17-000876
[2025-05-13T17:15:44.699+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:44.767+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:44.880+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2022/ALNY_10-Q_2022-04-28_0001178670-22-000016.txt
[2025-05-13T17:15:45.079+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:45.192+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy', 'HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['vutrisiran']}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['patisiran']}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': 'acute hepatic porphyria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['givosiran']}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria type 1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['lumasiran']}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['Leqvio']}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'complement-mediated diseases', 'preclinical_data': [], 'clinical_trials': ['Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}]}
[2025-05-13T17:15:45.355+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-21-000017
[2025-05-13T17:15:45.570+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2023/ALNY_10-Q_2023-05-04_0001178670-23-000011.txt
[2025-05-13T17:15:45.603+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 178122, Requested 50834. Please try again in 8.686s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:45.717+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:45.848+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hemophilia A and B with or without inhibitors', 'preclinical_data': [], 'clinical_trials': ['Phase 2 open label extension study, ongoing, safety event reported, dosing suspended'], 'upcoming_milestones': ['further review of the safety event', 'development of a risk mitigation strategy'], 'references': ['Item 8.01', '2017-09-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'acute hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['Item 8.01', '2017-09-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:45.913+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:45.984+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-16-007200
[2025-05-13T17:15:46.028+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 181001, Requested 45829. Please try again in 8.048s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:46.161+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['fitusiran']}, {'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, {'name': 'ALN-TTRsc02', 'mechanism_of_action': 'a subcutaneously administered investigational RNAi therapeutic in clinical development', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:46.553+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:46.734+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:46.924+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:47.048+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-10-05_0001193125-16-731590.txt
[2025-05-13T17:15:47.055+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 178707, Requested 50937. Please try again in 8.893s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:47.130+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:47.194+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:47.375+0000] {logging_mixin.py:190} INFO - Finished 20/191: 0001157523-22-001411
[2025-05-13T17:15:47.543+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-09-19_0001193125-16-713525.txt
[2025-05-13T17:15:47.802+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-08-04_0001157523-16-006448.txt
[2025-05-13T17:15:48.129+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 3.834000 seconds
[2025-05-13T17:15:48.191+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-06-15_0001193125-16-622502.txt
[2025-05-13T17:15:48.207+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-577773
[2025-05-13T17:15:48.391+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:48.473+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-17-000400
[2025-05-13T17:15:48.760+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:48.771+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:48.870+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:48.894+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2022/ALNY_10-Q_2022-07-28_0001178670-22-000020.txt
[2025-05-13T17:15:48.987+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:49.051+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-16-005377
[2025-05-13T17:15:49.073+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-535555
[2025-05-13T17:15:49.149+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-22-000016
[2025-05-13T17:15:49.171+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:49.189+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:49.382+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-462538
[2025-05-13T17:15:49.497+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 163615, Requested 51434. Please try again in 4.514s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:49.915+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 163176, Requested 50985. Please try again in 4.248s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:49.955+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-23-000011
[2025-05-13T17:15:49.961+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:50.048+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-16-004564
[2025-05-13T17:15:50.054+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 162349, Requested 50931. Please try again in 3.984s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:50.221+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 161614, Requested 50821. Please try again in 3.73s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:53.166+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:50.785+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2020/ALNY_10-Q_2020-11-05_0001178670-20-000019.txt
[2025-05-13T17:15:50.862+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:50.880+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-16-425799
[2025-05-13T17:15:50.889+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2020/ALNY_10-Q_2020-05-06_0001178670-20-000007.txt
[2025-05-13T17:15:50.912+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:50.989+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:51.088+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.621000 seconds
[2025-05-13T17:15:51.266+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-731590
[2025-05-13T17:15:51.273+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.308000 seconds
[2025-05-13T17:15:51.476+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis and Stargardt Disease', 'preclinical_data': [], 'clinical_trials': ['HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.'], 'upcoming_milestones': ['FDA review; extended PDUFA goal date of July 14, 2022.'], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}, {'name': 'zilebesiran (formerly ALN-AGT)', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, {'name': 'cemdisiran', 'mechanism_of_action': 'C5 small interfering RNA (siRNA)', 'target': 'C5 complement protein', 'indication': 'C5 complement-mediated diseases', 'preclinical_data': [], 'clinical_trials': ['Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'antithrombin', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}]}
[2025-05-13T17:15:51.637+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-410845
[2025-05-13T17:15:51.753+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-713525
[2025-05-13T17:15:52.012+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-16-006448
[2025-05-13T17:15:52.563+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:52.597+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-622502
[2025-05-13T17:15:52.643+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:52.764+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-22-000020
[2025-05-13T17:15:52.791+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-05-06_0001193125-16-582064.txt
[2025-05-13T17:15:52.825+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'polyneuropathy of hATTR amyloidosis in adults', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'PDUFA action date of October 8, 2023'], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly ALN-PCSsc']}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:53.047+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:53.079+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:15:50.281+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:15:53.386+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:53.165+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:53.594+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.498000 seconds
[2025-05-13T17:15:53.847+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-407792
[2025-05-13T17:15:53.890+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2019/ALNY_10-Q_2019-10-31_0001178670-19-000005.txt
[2025-05-13T17:15:54.018+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.333000 seconds
[2025-05-13T17:15:54.011+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:54.200+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'revusiran', 'mechanism_of_action': 'RNA interference therapeutic', 'target': '', 'indication': 'hereditary ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:54.362+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-371063
[2025-05-13T17:15:54.808+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:54.809+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:54.845+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-20-000019
[2025-05-13T17:15:54.890+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:56.353+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-15-002821
[2025-05-13T17:15:55.057+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:55.120+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:55.208+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-15-003798
[2025-05-13T17:15:55.272+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:55.361+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-20-000007
[2025-05-13T17:15:55.476+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {}}
[2025-05-13T17:15:55.482+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:55.509+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.826000 seconds
[2025-05-13T17:15:55.516+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:55.542+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:55.651+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.024+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.063+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.641000 seconds
[2025-05-13T17:15:56.072+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-336652
[2025-05-13T17:15:56.113+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.148+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.204+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.802000 seconds
[2025-05-13T17:15:56.242+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:56.272+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-582064
[2025-05-13T17:15:56.289+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-282067
[2025-05-13T17:15:56.298+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria (PH)', 'preclinical_data': [], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019'], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:55.035+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:56.455+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-252425
[2025-05-13T17:15:56.564+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.736000 seconds
[2025-05-13T17:15:56.602+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:15:56.639+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.651+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-05-02_0001157523-16-005377.txt
[2025-05-13T17:15:56.702+0000] {logging_mixin.py:190} INFO - Finished 21/191: 0001193125-23-253084
[2025-05-13T17:15:56.724+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.853+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-04-08_0001193125-16-535555.txt
[2025-05-13T17:15:56.889+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.663000 seconds
[2025-05-13T17:15:56.889+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:56.959+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 191718, Requested 36815. Please try again in 8.559s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:56.960+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-19-000005
[2025-05-13T17:15:56.870+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:57.019+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:57.120+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:57.137+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.553000 seconds
[2025-05-13T17:15:57.210+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.643000 seconds
[2025-05-13T17:15:57.432+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.612000 seconds
[2025-05-13T17:15:57.470+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 4.461000 seconds
[2025-05-13T17:15:57.566+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-02-11_0001157523-16-004564.txt
[2025-05-13T17:15:57.773+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:57.895+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:57.867+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:57.993+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2016/ALNY_8-K_2016-01-11_0001193125-16-425799.txt
[2025-05-13T17:15:58.052+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-250381
[2025-05-13T17:15:58.059+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:58.091+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-219361
[2025-05-13T17:15:58.440+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-178432
[2025-05-13T17:15:58.719+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.398000 seconds
[2025-05-13T17:15:58.743+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:58.782+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:15:58.946+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin', 'indication': 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'FILING DATE: 2023-10-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}]}
[2025-05-13T17:15:58.720+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:59.019+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.292000 seconds
[2025-05-13T17:15:59.086+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:15:59.306+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.107000 seconds
[2025-05-13T17:15:59.344+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:15:59.389+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:15:59.365+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-12-22_0001193125-15-410845.txt
[2025-05-13T17:15:59.544+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 189506, Requested 50813. Please try again in 12.095s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:15:59.781+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 188766, Requested 51211. Please try again in 11.993s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:02.400+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:16:00.341+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-16-005377
[2025-05-13T17:16:00.544+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-15-001675
[2025-05-13T17:16:00.571+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.879000 seconds
[2025-05-13T17:16:00.730+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-535555
[2025-05-13T17:16:01.179+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-12-18_0001193125-15-407792.txt
[2025-05-13T17:16:01.282+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.250000 seconds
[2025-05-13T17:16:01.634+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-11-09_0001157523-15-003798.txt
[2025-05-13T17:16:01.659+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:01.724+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:01.854+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.297000 seconds
[2025-05-13T17:16:02.033+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-16-004564
[2025-05-13T17:16:03.486+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:02.183+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.911000 seconds
[2025-05-13T17:16:02.223+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:02.229+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-08-06_0001157523-15-002821.txt
[2025-05-13T17:16:02.263+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-425799
[2025-05-13T17:15:59.804+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:02.507+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:02.700+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-10-02_0001193125-15-336652.txt
[2025-05-13T17:16:02.670+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:02.902+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:04.114+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-15-000553
[2025-05-13T17:16:03.205+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-410845
[2025-05-13T17:16:03.259+0000] {logging_mixin.py:190} INFO - Finished 22/191: 0001193125-23-202313
[2025-05-13T17:16:03.357+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:02.104+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-172191
[2025-05-13T17:16:03.535+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-119442
[2025-05-13T17:16:03.872+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:05.050+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-031716
[2025-05-13T17:16:03.093+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:04.175+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:04.192+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:04.200+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2021/ALNY_10-Q_2021-08-03_0001178670-21-000024.txt
[2025-05-13T17:16:04.230+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:04.271+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:04.277+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:04.445+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-407792
[2025-05-13T17:16:05.869+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:03.979+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-050223
[2025-05-13T17:16:05.469+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-020438
[2025-05-13T17:16:05.544+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:05.590+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-15-002821
[2025-05-13T17:16:06.642+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:05.721+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:04.545+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-15-003798
[2025-05-13T17:16:05.893+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-010741
[2025-05-13T17:16:06.060+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-06-10_0001193125-15-219361.txt
[2025-05-13T17:16:06.185+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:06.293+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-336652
[2025-05-13T17:16:06.470+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.057000 seconds
[2025-05-13T17:16:06.597+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-07-14_0001193125-15-252425.txt
[2025-05-13T17:16:05.671+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.358000 seconds
[2025-05-13T17:16:06.643+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-15-004485
[2025-05-13T17:16:06.678+0000] {logging_mixin.py:190} INFO - Finished 23/191: 0001193125-23-179631
[2025-05-13T17:16:07.693+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Item 8.01', 'Filing date: 2023-06-30', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:06.942+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2024/ALNY_10-K_2024-02-15_0001178670-24-000008.txt
[2025-05-13T17:16:07.022+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-21-000024
[2025-05-13T17:16:07.141+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:07.192+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:07.222+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-07-10_0001193125-15-250381.txt
[2025-05-13T17:16:07.266+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:08.318+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-447755
[2025-05-13T17:16:07.493+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:06.756+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:07.706+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:07.961+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2023/ALNY_10-K_2023-02-23_0001178670-23-000005.txt
[2025-05-13T17:16:07.961+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:08.940+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-399866
[2025-05-13T17:16:08.058+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:07.239+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:08.368+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:08.407+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:08.638+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-02-12_0001157523-15-000553.txt
[2025-05-13T17:16:08.661+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.430000 seconds
[2025-05-13T17:16:08.671+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:08.725+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:08.761+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-446129
[2025-05-13T17:16:08.797+0000] {logging_mixin.py:190} INFO - Finished 24/191: 0001157523-23-001622
[2025-05-13T17:16:08.854+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-219361
[2025-05-13T17:16:10.290+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:09.126+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:09.132+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-252425
[2025-05-13T17:16:09.162+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.717000 seconds
[2025-05-13T17:16:09.259+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:09.317+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:09.471+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-05-05_0001193125-15-172191.txt
[2025-05-13T17:16:09.482+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-04-06_0001193125-15-119442.txt
[2025-05-13T17:16:09.418+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-24-000008
[2025-05-13T17:16:09.513+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.351000 seconds
[2025-05-13T17:16:09.538+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:10.077+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 190316, Requested 43201. Please try again in 10.055s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:10.080+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:10.233+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:10.245+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-250381
[2025-05-13T17:16:08.002+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-05-07_0001157523-15-001675.txt
[2025-05-13T17:16:10.333+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-14-004401
[2025-05-13T17:16:10.375+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.304000 seconds
[2025-05-13T17:16:10.404+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:10.867+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-01-26_0001193125-15-020438.txt
[2025-05-13T17:16:11.018+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-23-000005
[2025-05-13T17:16:11.033+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:11.145+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-02-03_0001193125-15-031716.txt
[2025-05-13T17:16:11.236+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.596000 seconds
[2025-05-13T17:16:11.430+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:11.489+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:11.606+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-01-14_0001193125-15-010741.txt
[2025-05-13T17:16:11.649+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:11.702+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:11.725+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:11.790+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-15-000553
[2025-05-13T17:16:11.822+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-354903
[2025-05-13T17:16:11.863+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'TTR protein', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['ONPATTRO']}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'GAPDH', 'indication': 'Primary Hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:11.875+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-301873
[2025-05-13T17:16:11.881+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:12.056+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2015/ALNY_8-K_2015-01-08_0001193125-15-004485.txt
[2025-05-13T17:16:12.224+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-172191
[2025-05-13T17:16:12.791+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:12.820+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-192579
[2025-05-13T17:16:12.454+0000] {logging_mixin.py:190} INFO - Finished 25/191: 0001193125-23-245768
[2025-05-13T17:16:12.456+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-119442
[2025-05-13T17:16:12.540+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:12.606+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:12.612+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2019/ALNY_10-Q_2019-05-02_0001564590-19-015366.txt
[2025-05-13T17:16:12.664+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:12.701+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:12.702+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-258369
[2025-05-13T17:16:12.740+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.903000 seconds
[2025-05-13T17:16:12.763+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-12-19_0001193125-14-447755.txt
[2025-05-13T17:16:12.313+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.075000 seconds
[2025-05-13T17:16:12.374+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-14-003397
[2025-05-13T17:16:12.853+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:13.890+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:12.921+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:12.950+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-14-002039
[2025-05-13T17:16:12.968+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-020438
[2025-05-13T17:16:12.973+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.491000 seconds
[2025-05-13T17:16:13.004+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:13.063+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-15-001675
[2025-05-13T17:16:13.141+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.049000 seconds
[2025-05-13T17:16:13.149+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175978, Requested 24049. Please try again in 8ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:13.150+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-010741
[2025-05-13T17:16:14.845+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:13.286+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2018/ALNY_10-Q_2018-08-02_0001564590-18-018696.txt
[2025-05-13T17:16:13.828+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-12-18_0001193125-14-446129.txt
[2025-05-13T17:16:12.920+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:14.037+0000] {logging_mixin.py:190} INFO - Finished 26/191: 0001193125-23-151845
[2025-05-13T17:16:15.170+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:14.329+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-004485
[2025-05-13T17:16:15.381+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:14.403+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:14.604+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-19-015366
[2025-05-13T17:16:15.891+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:15.976+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-073378
[2025-05-13T17:16:14.761+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:14.835+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:16.212+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172714, Requested 51224. Please try again in 7.181s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:14.852+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-128105
[2025-05-13T17:16:14.891+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:14.960+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:15.162+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-112393
[2025-05-13T17:16:14.244+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.173000 seconds
[2025-05-13T17:16:15.173+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:15.208+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:15.285+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:14.379+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:15.389+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:15.444+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-085635
[2025-05-13T17:16:15.611+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-447755
[2025-05-13T17:16:15.631+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 171819, Requested 50978. Please try again in 6.839s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:17.095+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:14.616+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:14.645+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:16.086+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:13.199+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-031716
[2025-05-13T17:16:16.221+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:16:16.238+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:16.314+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-11-05_0001157523-14-004401.txt
[2025-05-13T17:16:16.396+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172105, Requested 50958. Please try again in 6.918s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:17.787+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:16.794+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 170862, Requested 50857. Please try again in 6.515s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:16.883+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-18-018696
[2025-05-13T17:16:16.968+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-068393
[2025-05-13T17:16:16.922+0000] {logging_mixin.py:190} INFO - Finished 27/191: 0001193125-23-194715
[2025-05-13T17:16:17.018+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 170707, Requested 50895. Please try again in 6.48s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:18.282+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:17.064+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:18.425+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-14-000620
[2025-05-13T17:16:17.148+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-060913
[2025-05-13T17:16:17.263+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172126, Requested 50903. Please try again in 6.908s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:17.372+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.013000 seconds
[2025-05-13T17:16:17.377+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:18.923+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.593000 seconds
[2025-05-13T17:16:17.468+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:17.599+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-446129
[2025-05-13T17:16:19.139+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:17.780+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:16.452+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.789000 seconds
[2025-05-13T17:16:17.898+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-07-02_0001193125-14-258369.txt
[2025-05-13T17:16:17.917+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:18.026+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:18.093+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:18.215+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'zilebesiran', 'mechanism_of_action': 'siRNA therapeutic targeting liver-expressed angiotensinogen', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Item 1.01', 'Filing Date: 2023-07-26', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:17.043+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:18.325+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:18.383+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:15.609+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:18.420+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:18.636+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-08-07_0001157523-14-003397.txt
[2025-05-13T17:16:18.700+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:18.912+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-14-004401
[2025-05-13T17:16:17.422+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:19.107+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:17.687+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2019/ALNY_10-Q_2019-08-06_0001564590-19-029367.txt
[2025-05-13T17:16:19.150+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-008903
[2025-05-13T17:16:19.547+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-14-008836
[2025-05-13T17:16:19.581+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:19.601+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:19.721+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:19.811+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:19.854+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:19.989+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 191417, Requested 36869. Please try again in 8.485s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:20.935+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:20.083+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:20.271+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-13-431609
[2025-05-13T17:16:20.319+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-04-02_0001193125-14-128105.txt
[2025-05-13T17:16:20.535+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 4.024000 seconds
[2025-05-13T17:16:20.629+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-258369
[2025-05-13T17:16:24.516+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:20.735+0000] {logging_mixin.py:190} INFO - Finished 28/191: 0001193125-22-077831
[2025-05-13T17:16:24.649+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:20.797+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:20.838+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 11.885000 seconds
[2025-05-13T17:16:20.888+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-03-24_0001193125-14-112393.txt
[2025-05-13T17:16:20.935+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-09-26_0001193125-14-354903.txt
[2025-05-13T17:16:20.035+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:22.123+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-03-06_0001193125-14-085635.txt
[2025-05-13T17:16:22.989+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-05-08_0001157523-14-002039.txt
[2025-05-13T17:16:22.840+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-13-005351
[2025-05-13T17:16:23.135+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:23.175+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:23.456+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:23.494+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:23.519+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-14-003397
[2025-05-13T17:16:23.596+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:24.466+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:24.453+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:20.667+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-02-27_0001193125-14-073378.txt
[2025-05-13T17:16:24.543+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-13-328105
[2025-05-13T17:16:20.773+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 189056, Requested 37421. Please try again in 7.943s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:24.664+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:24.712+0000] {logging_mixin.py:190} INFO - Failed to upload 10-K filing to GCS: ALNY/10-K/2025/ALNY_10-K_2025-02-13_0001178670-25-000026.txt
[2025-05-13T17:16:24.724+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:24.778+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 189100, Requested 39667. Please try again in 8.63s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:28.506+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:24.821+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-02-13_0001157523-14-000620.txt
[2025-05-13T17:16:24.941+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2017/ALNY_10-Q_2017-11-07_0001564590-17-022281.txt
[2025-05-13T17:16:25.063+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-02-26_0001193125-14-068393.txt
[2025-05-13T17:16:25.148+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:29.044+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172878, Requested 50885. Please try again in 7.128s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:25.965+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-128105
[2025-05-13T17:16:29.257+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:26.031+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:26.804+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.773000 seconds
[2025-05-13T17:16:26.849+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-112393
[2025-05-13T17:16:26.957+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.488000 seconds
[2025-05-13T17:16:26.987+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 178510, Requested 31833. Please try again in 3.102s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:27.248+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:27.413+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.338000 seconds
[2025-05-13T17:16:27.483+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-085635
[2025-05-13T17:16:27.633+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175321, Requested 50861. Please try again in 7.854s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:27.898+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-354903
[2025-05-13T17:16:27.994+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:28.011+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:28.206+0000] {logging_mixin.py:190} INFO - Finished 29/191: 0001157523-24-000253
[2025-05-13T17:16:28.234+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-14-002039
[2025-05-13T17:16:28.289+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000026
[2025-05-13T17:16:28.424+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2016/ALNY_10-Q_2016-11-03_0001193125-16-758802.txt
[2025-05-13T17:16:24.820+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-19-029367
[2025-05-13T17:16:28.533+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172008, Requested 50916. Please try again in 6.877s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:28.765+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:25.301+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:29.088+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:29.147+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2016/ALNY_10-Q_2016-08-04_0001193125-16-671945.txt
[2025-05-13T17:16:29.245+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-073378
[2025-05-13T17:16:25.976+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:29.347+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-13-004008
[2025-05-13T17:16:29.761+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:29.838+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:30.084+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-13-253522
[2025-05-13T17:16:30.088+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2017/ALNY_10-Q_2017-05-05_0001564590-17-008948.txt
[2025-05-13T17:16:30.169+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-14-000620
[2025-05-13T17:16:33.169+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:30.428+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:30.464+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:30.584+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:30.591+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-17-022281
[2025-05-13T17:16:30.773+0000] {logging_mixin.py:190} INFO - Failed to upload 10-Q filing to GCS: ALNY/10-Q/2018/ALNY_10-Q_2018-11-07_0001564590-18-028070.txt
[2025-05-13T17:16:30.793+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 168269, Requested 50964. Please try again in 5.769s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:31.083+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:31.113+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-01-13_0001193125-14-008836.txt
[2025-05-13T17:16:31.281+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:31.374+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:16:31.749+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:31.874+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:31.956+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:32.277+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.981000 seconds
[2025-05-13T17:16:32.463+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:32.579+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:32.607+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.853000 seconds
[2025-05-13T17:16:32.751+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:32.779+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-13-204676
[2025-05-13T17:16:33.168+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2020/ALNY_10-Q_2020-08-06_0001178670-20-000015.txt
[2025-05-13T17:16:30.289+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-068393
[2025-05-13T17:16:33.248+0000] {logging_mixin.py:190} INFO - Processing filing: 0001157523-13-002380
[2025-05-13T17:16:33.272+0000] {logging_mixin.py:190} INFO - Processing filing: 0001193125-13-065475
[2025-05-13T17:16:33.556+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-758802
[2025-05-13T17:16:33.596+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:33.704+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-18-028070
[2025-05-13T17:16:33.812+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:33.845+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:34.217+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2013/ALNY_8-K_2013-11-06_0001157523-13-005351.txt
[2025-05-13T17:16:34.386+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing date: 2023-06-30', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:34.440+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2015/ALNY_10-Q_2015-05-08_0001193125-15-178432.txt
[2025-05-13T17:16:34.492+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:34.515+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-671945
[2025-05-13T17:16:34.594+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-17-008948
[2025-05-13T17:16:34.808+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:34.831+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.202000 seconds
[2025-05-13T17:16:34.840+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:35.008+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.540000 seconds
[2025-05-13T17:16:35.084+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.408000 seconds
[2025-05-13T17:16:35.175+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:35.219+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:35.429+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:35.451+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:35.577+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:16:35.658+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.411000 seconds
[2025-05-13T17:16:35.941+0000] {logging_mixin.py:190} INFO - Finished 30/191: 0001193125-24-003854
[2025-05-13T17:16:36.091+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-008836
[2025-05-13T17:16:36.147+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017'], 'upcoming_milestones': [], 'references': ['ITEM 5, August 2, 2016 SEC Filing'], 'aliases': []}]}
[2025-05-13T17:16:36.202+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:36.270+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.061000 seconds
[2025-05-13T17:16:36.664+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:36.829+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-20-000015
[2025-05-13T17:16:36.925+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.108000 seconds
[2025-05-13T17:16:37.119+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:37.125+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-13-005351
[2025-05-13T17:16:37.142+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2024-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:37.171+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2013/ALNY_8-K_2013-08-08_0001157523-13-004008.txt
[2025-05-13T17:16:37.191+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:37.460+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-178432
[2025-05-13T17:16:37.602+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:37.610+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2014/ALNY_8-K_2014-01-13_0001193125-14-008903.txt
[2025-05-13T17:16:37.732+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.263000 seconds
[2025-05-13T17:16:37.934+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:37.965+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:37.975+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:38.065+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:38.208+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:38.301+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:39.021+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:39.031+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2013/ALNY_8-K_2013-06-10_0001193125-13-253522.txt
[2025-05-13T17:16:39.069+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:39.233+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:39.260+0000] {logging_mixin.py:190} INFO - Uploaded 8-K filing to GCS: gs://clinical_data_may25/ALNY/8-K/2013/ALNY_8-K_2013-05-06_0001157523-13-002380.txt
[2025-05-13T17:16:39.346+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.135000 seconds
[2025-05-13T17:16:39.351+0000] {logging_mixin.py:190} INFO - Finished 31/191: 0001193125-22-096176
[2025-05-13T17:16:39.598+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 173806, Requested 50931. Please try again in 7.421s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:39.710+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-13-004008
[2025-05-13T17:16:39.746+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172743, Requested 50981. Please try again in 7.117s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:40.195+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:40.040+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:40.095+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-008903
[2025-05-13T17:16:40.117+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:40.182+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:39.899+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 172079, Requested 50828. Please try again in 6.872s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:40.283+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:40.303+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'TTR amyloid cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-AS1', 'mechanism_of_action': '', 'target': '', 'indication': 'hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:40.400+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:40.450+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:40.520+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:40.607+0000] {logging_mixin.py:190} INFO - Finished 32/191: 0001193125-22-094409
[2025-05-13T17:16:40.666+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 2.087000 seconds
[2025-05-13T17:16:40.762+0000] {logging_mixin.py:190} INFO - Failed to upload 10-Q filing to GCS: ALNY/10-Q/2017/ALNY_10-Q_2017-08-09_0001564590-17-016993.txt
[2025-05-13T17:16:40.853+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Item 8.01', 'Filing Date: 2022-04-04', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:40.924+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:40.992+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-17-016993
[2025-05-13T17:16:41.102+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:41.102+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.473000 seconds
[2025-05-13T17:16:41.128+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:16:41.156+0000] {logging_mixin.py:190} INFO - Finished processing: 0001157523-13-002380
[2025-05-13T17:16:41.274+0000] {logging_mixin.py:190} INFO - Finished 33/191: 0001193125-23-004109
[2025-05-13T17:16:41.295+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-13-253522
[2025-05-13T17:16:41.332+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:41.573+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:41.632+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2023-01-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:41.712+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:41.739+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2016/ALNY_10-Q_2016-05-04_0001193125-16-577773.txt
[2025-05-13T17:16:41.830+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.227000 seconds
[2025-05-13T17:16:42.022+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:42.229+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2018/ALNY_10-Q_2018-05-04_0001564590-18-011031.txt
[2025-05-13T17:16:42.236+0000] {logging_mixin.py:190} INFO - Finished 34/191: 0001193125-22-173444
[2025-05-13T17:16:42.409+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin', 'indication': 'polyneuropathy of hereditary transthyretin-mediated amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2022-06-14', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm'], 'aliases': ['vutrisiran']}]}
[2025-05-13T17:16:42.417+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:42.418+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:42.577+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 185850, Requested 50981. Please try again in 11.049s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:42.590+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:42.591+0000] {logging_mixin.py:190} INFO - Finished 35/191: 0001157523-22-000494
[2025-05-13T17:16:42.592+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:42.716+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.917000 seconds
[2025-05-13T17:16:42.728+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:42.879+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:42.911+0000] {logging_mixin.py:190} INFO - Finished 36/191: 0001193125-22-157503
[2025-05-13T17:16:42.972+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:42.995+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:43.031+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:43.050+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.052000 seconds
[2025-05-13T17:16:43.132+0000] {logging_mixin.py:190} INFO - Finished 37/191: 0001157523-22-000175
[2025-05-13T17:16:43.262+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:43.293+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:43.337+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-577773
[2025-05-13T17:16:43.398+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, completed enrollment, data expected in 2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:43.407+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:43.418+0000] {logging_mixin.py:190} INFO - Finished 38/191: 0001193125-21-310422
[2025-05-13T17:16:43.480+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 192443, Requested 50935. Please try again in 13.013s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:43.497+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:43.522+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:43.529+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-18-011031
[2025-05-13T17:16:43.548+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:43.567+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:43.599+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018'], 'upcoming_milestones': ['Regulatory approval in the U.S. and EU'], 'references': ['SEC filing details, November 2017'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': '', 'target': '', 'indication': 'AIP', 'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['SEC filing details, April 2018'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': ['Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE'], 'upcoming_milestones': ['Resumption of dosing in clinical studies'], 'references': ['SEC filing details, September 2017'], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension'], 'upcoming_milestones': [], 'references': ['SEC filing details, October 2016'], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': 'advanced pancreatic neuroendocrine cancer', 'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient'], 'upcoming_milestones': [], 'references': ['SEC filing details'], 'aliases': []}]}
[2025-05-13T17:16:43.680+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.143000 seconds
[2025-05-13T17:16:43.743+0000] {logging_mixin.py:190} INFO - Finished 39/191: 0001193125-22-005024
[2025-05-13T17:16:43.775+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:43.809+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:43.840+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:43.880+0000] {logging_mixin.py:190} INFO - Finished 40/191: 0001193125-21-267358
[2025-05-13T17:16:43.892+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.537000 seconds
[2025-05-13T17:16:43.900+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.034+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.067+0000] {logging_mixin.py:190} INFO - Finished 41/191: 0001193125-21-169325
[2025-05-13T17:16:44.105+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.128+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.188+0000] {logging_mixin.py:190} INFO - Finished 42/191: 0001193125-21-362387
[2025-05-13T17:16:44.200+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.609+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.640+0000] {logging_mixin.py:190} INFO - Finished 43/191: 0001193125-21-234071
[2025-05-13T17:16:44.643+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.646+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.649+0000] {logging_mixin.py:190} INFO - Finished 44/191: 0001193125-22-001706
[2025-05-13T17:16:44.650+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.677+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.865+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:44.866+0000] {logging_mixin.py:190} INFO - Finished 45/191: 0001157523-21-000536
[2025-05-13T17:16:44.878+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.097000 seconds
[2025-05-13T17:16:44.889+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:44.944+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:44.988+0000] {logging_mixin.py:190} INFO - Finished 46/191: 0001193125-21-113304
[2025-05-13T17:16:44.990+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:45.002+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2021-04-12', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm'], 'aliases': ['patisiran']}]}
[2025-05-13T17:16:45.009+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.066000 seconds
[2025-05-13T17:16:45.049+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:45.049+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.078+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.916000 seconds
[2025-05-13T17:16:45.133+0000] {logging_mixin.py:190} INFO - Finished 47/191: 0001157523-21-000169
[2025-05-13T17:16:45.150+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.168+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:45.175+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.803000 seconds
[2025-05-13T17:16:45.181+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.214+0000] {logging_mixin.py:190} INFO - Finished 48/191: 0001157523-20-001446
[2025-05-13T17:16:45.226+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.243+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.265+0000] {logging_mixin.py:190} INFO - Finished 49/191: 0001193125-20-262507
[2025-05-13T17:16:45.282+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.294+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 0.816160 seconds
[2025-05-13T17:16:45.306+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.329+0000] {logging_mixin.py:190} INFO - Finished 50/191: 0001157523-20-001145
[2025-05-13T17:16:45.340+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.357+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.380+0000] {logging_mixin.py:190} INFO - Finished 51/191: 0001157523-20-000673
[2025-05-13T17:16:45.391+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.407+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.435+0000] {logging_mixin.py:190} INFO - Finished 52/191: 0001193125-20-139137
[2025-05-13T17:16:45.441+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.457+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.479+0000] {logging_mixin.py:190} INFO - Finished 53/191: 0001178670-24-000053
[2025-05-13T17:16:45.485+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:45.508+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022'], 'references': ['Filing Date: 2022-04-04', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy']}}}
[2025-05-13T17:16:45.530+0000] {logging_mixin.py:190} INFO - Finished 54/191: 0001193125-20-225661
[2025-05-13T17:16:45.541+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, {'name': 'ALN-AGT', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:45.564+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval in specified countries'], 'references': ['Filing Date: 2022-04-04', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.588+0000] {logging_mixin.py:190} INFO - Finished 55/191: 0001193125-21-005849
[2025-05-13T17:16:45.599+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2021-01-11', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:45.621+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval in specified countries'], 'references': ['Filing Date: 2022-04-04', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.649+0000] {logging_mixin.py:190} INFO - Finished 56/191: 0001193125-20-052682
[2025-05-13T17:16:45.655+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.677+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': ['FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval in specified countries'], 'references': ['Filing Date: 2022-04-04', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.710+0000] {logging_mixin.py:190} INFO - Finished 57/191: 0001178670-24-000023
[2025-05-13T17:16:45.722+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic targeting TTR', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': 'RNAi therapeutic targeting TTR', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3, investigating cardiac manifestations, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic targeting antithrombin', 'target': 'antithrombin', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic targeting LPHN1', 'target': 'LPHN1', 'indication': 'primary hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}]}
[2025-05-13T17:16:45.734+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Item 2.02', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.756+0000] {logging_mixin.py:190} INFO - Finished 58/191: 0001178670-24-000041
[2025-05-13T17:16:45.768+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3, positive topline results reported'], 'upcoming_milestones': ['Regulatory approval for broader indication'], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 5', 'Filing Date: 2024-08-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm'], 'aliases': []}]}
[2025-05-13T17:16:45.780+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}}}
[2025-05-13T17:16:45.807+0000] {logging_mixin.py:190} INFO - Finished 59/191: 0001178670-25-000052
[2025-05-13T17:16:45.820+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Alzheimer’s Disease', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nucresiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inotersen', 'mechanism_of_action': 'antisense drug', 'target': 'specific genes', 'indication': 'adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'WAINUA', 'mechanism_of_action': 'antisense drug', 'target': 'specific genes', 'indication': 'not specified', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}]}
[2025-05-13T17:16:45.832+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:45.839+0000] {logging_mixin.py:190} INFO - Finished 60/191: 0001193125-20-005791
[2025-05-13T17:16:45.845+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'FILING DATE: 2020-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'FILING DATE: 2020-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:45.862+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:45.880+0000] {logging_mixin.py:190} INFO - Finished 61/191: 0001193125-19-296636
[2025-05-13T17:16:45.886+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': 'acute hepatic porphyria (AHP)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', '2019-11-20', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm'], 'aliases': ['givosiran']}]}
[2025-05-13T17:16:45.904+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:45.917+0000] {logging_mixin.py:190} INFO - Finished 62/191: 0001157523-19-002155
[2025-05-13T17:16:45.923+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:45.951+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:45.940+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:45.970+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.042000 seconds
[2025-05-13T17:16:45.999+0000] {logging_mixin.py:190} INFO - Finished 63/191: 0001193125-20-105270
[2025-05-13T17:16:46.005+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.017+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:46.040+0000] {logging_mixin.py:190} INFO - Finished 64/191: 0001193125-19-192410
[2025-05-13T17:16:46.052+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.069+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}}}
[2025-05-13T17:16:46.075+0000] {logging_mixin.py:190} INFO - Finished 65/191: 0001193125-20-099010
[2025-05-13T17:16:46.082+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'lumasiran', 'mechanism_of_action': 'RNA interference targeting glycolate oxidase', 'target': 'glycolate oxidase', 'indication': 'primary hyperoxaluria type 1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, {'name': 'ALN-AAT02', 'mechanism_of_action': 'RNA interference', 'target': '', 'indication': 'alpha-1 antitrypsin deficiency-associated liver disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Item 8.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, {'name': 'DCR-A1AT', 'mechanism_of_action': 'RNA interference', 'target': '', 'indication': 'alpha-1 antitrypsin deficiency-associated liver disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2020-04-06', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.094+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.106+0000] {logging_mixin.py:190} INFO - Finished 66/191: 0001157523-20-000164
[2025-05-13T17:16:46.113+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.130+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.147+0000] {logging_mixin.py:190} INFO - Finished 67/191: 0001193125-19-261686
[2025-05-13T17:16:46.158+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.176+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.188+0000] {logging_mixin.py:190} INFO - Finished 68/191: 0001157523-19-001714
[2025-05-13T17:16:46.194+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.206+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.223+0000] {logging_mixin.py:190} INFO - Finished 69/191: 0001157523-19-001001
[2025-05-13T17:16:46.230+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.206+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:46.242+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.312+0000] {logging_mixin.py:190} INFO - Finished 70/191: 0001193125-19-152751
[2025-05-13T17:16:46.334+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.354+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.357+0000] {logging_mixin.py:190} INFO - Finished 71/191: 0001157523-19-000264
[2025-05-13T17:16:46.358+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.361+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.363+0000] {logging_mixin.py:190} INFO - Finished 72/191: 0001193125-19-122475
[2025-05-13T17:16:46.363+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.365+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.367+0000] {logging_mixin.py:190} INFO - Finished 73/191: 0001193125-19-003205
[2025-05-13T17:16:46.367+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 2.02', 'Filing Date: 2019-01-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.369+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.371+0000] {logging_mixin.py:190} INFO - Finished 74/191: 0001193125-19-009888
[2025-05-13T17:16:46.372+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.374+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.376+0000] {logging_mixin.py:190} INFO - Finished 75/191: 0001193125-19-101737
[2025-05-13T17:16:46.377+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Item 1.01', 'Filing Date: 2019-04-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2019-04-09', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}]}
[2025-05-13T17:16:46.378+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}}}
[2025-05-13T17:16:46.380+0000] {logging_mixin.py:190} INFO - Finished 76/191: 0001193125-18-296858
[2025-05-13T17:16:46.381+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.382+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}}}
[2025-05-13T17:16:46.383+0000] {logging_mixin.py:190} INFO - Finished 77/191: 0001193125-18-290906
[2025-05-13T17:16:46.384+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.385+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}}}
[2025-05-13T17:16:46.387+0000] {logging_mixin.py:190} INFO - Finished 78/191: 0001178670-23-000015
[2025-05-13T17:16:46.389+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.391+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.393+0000] {logging_mixin.py:190} INFO - Finished 79/191: 0001157523-18-002349
[2025-05-13T17:16:46.394+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.395+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.397+0000] {logging_mixin.py:190} INFO - Finished 80/191: 0001193125-18-251725
[2025-05-13T17:16:46.397+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.399+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.401+0000] {logging_mixin.py:190} INFO - Finished 81/191: 0001193125-18-245969
[2025-05-13T17:16:46.401+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-08-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.403+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.404+0000] {logging_mixin.py:190} INFO - Finished 82/191: 0001157523-18-001671
[2025-05-13T17:16:46.405+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.407+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.409+0000] {logging_mixin.py:190} INFO - Finished 83/191: 0001193125-18-164173
[2025-05-13T17:16:46.409+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.411+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.412+0000] {logging_mixin.py:190} INFO - Finished 84/191: 0001193125-18-125102
[2025-05-13T17:16:46.413+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.414+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.415+0000] {logging_mixin.py:190} INFO - Finished 85/191: 0001157523-18-000981
[2025-05-13T17:16:46.416+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.417+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.419+0000] {logging_mixin.py:190} INFO - Finished 86/191: 0001193125-18-346287
[2025-05-13T17:16:46.420+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'ALN-HBV02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, {'name': 'ALN-AAT02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 8.01', 'Filing Date: 2018-12-10', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.421+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.424+0000] {logging_mixin.py:190} INFO - Finished 87/191: 0001193125-18-106272
[2025-05-13T17:16:46.425+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'FILING DATE: 2018-04-03', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.426+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.428+0000] {logging_mixin.py:190} INFO - Finished 88/191: 0001157523-18-000252
[2025-05-13T17:16:46.429+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.430+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['acute hepatic porphyria (AHP)']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': []}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.432+0000] {logging_mixin.py:190} INFO - Finished 89/191: 0001178670-21-000028
[2025-05-13T17:16:46.444+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': 'Investigational RNAi therapeutic', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['HELIOS-A Phase 3 study, positive topline results, January 2021', 'NDA submitted to FDA in April 2021, accepted by FDA', 'FDA action date set for April 14, 2022', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Submitted MAA in EU with EMA in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'AHP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'Investigational RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Hemophilia', 'preclinical_data': [], 'clinical_trials': ['Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'Potential filing date moved to 2024'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Atypical hemolytic uremic syndrome', 'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.449+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['primary hyperoxaluria'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': [], 'aliases': []}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.452+0000] {logging_mixin.py:190} INFO - Finished 90/191: 0001178670-23-000023
[2025-05-13T17:16:46.453+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'eplontersen', 'mechanism_of_action': '', 'target': '', 'indication': 'polyneuropathy of hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'acoramidis', 'mechanism_of_action': 'TTR stabilizer', 'target': 'TTR', 'indication': 'ATTR-CM', 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'once-monthly subcutaneous RNAi therapy', 'target': '', 'indication': 'primary hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, {'name': 'inotersen', 'mechanism_of_action': 'antisense drug', 'target': '', 'indication': 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}]}
[2025-05-13T17:16:46.455+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.458+0000] {logging_mixin.py:190} INFO - Finished 91/191: 0001193125-18-082339
[2025-05-13T17:16:46.466+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.468+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:46.470+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 188537, Requested 50848. Please try again in 11.815s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:46.469+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.471+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:46.480+0000] {logging_mixin.py:190} INFO - Finished 92/191: 0001193125-17-342673
[2025-05-13T17:16:46.481+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.483+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.485+0000] {logging_mixin.py:190} INFO - Finished 93/191: 0001193125-17-182644
[2025-05-13T17:16:46.486+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.488+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.489+0000] {logging_mixin.py:190} INFO - Finished 94/191: 0001157523-17-002334
[2025-05-13T17:16:46.490+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.491+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.493+0000] {logging_mixin.py:190} INFO - Finished 95/191: 0001193125-17-195385
[2025-05-13T17:16:46.494+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.495+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.496+0000] {logging_mixin.py:190} INFO - Finished 96/191: 0001157523-17-003038
[2025-05-13T17:16:46.497+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.498+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.500+0000] {logging_mixin.py:190} INFO - Finished 97/191: 0001193125-18-001686
[2025-05-13T17:16:46.500+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.501+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.503+0000] {logging_mixin.py:190} INFO - Finished 98/191: 0001193125-17-163465
[2025-05-13T17:16:46.504+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.505+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023'], 'references': ['FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': [], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': []}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.507+0000] {logging_mixin.py:190} INFO - Finished 99/191: 0001178670-22-000026
[2025-05-13T17:16:46.508+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:46.509+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy', 'HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['vutrisiran']}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['patisiran']}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': 'acute hepatic porphyria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['givosiran']}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria type 1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['lumasiran']}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': ['Leqvio']}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'cemdisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'complement-mediated diseases', 'preclinical_data': [], 'clinical_trials': ['Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.512+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.514+0000] {logging_mixin.py:190} INFO - Finished 100/191: 0001157523-17-001455
[2025-05-13T17:16:46.515+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.523+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:46.522+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': [], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.535+0000] {logging_mixin.py:190} INFO - Finished 101/191: 0001193125-17-278495
[2025-05-13T17:16:46.539+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hemophilia A and B with or without inhibitors', 'preclinical_data': [], 'clinical_trials': ['Phase 2 open label extension study, ongoing, safety event reported, dosing suspended'], 'upcoming_milestones': ['further review of the safety event', 'development of a risk mitigation strategy'], 'references': ['Item 8.01', '2017-09-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'acute hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['Item 8.01', '2017-09-07', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.541+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}}}
[2025-05-13T17:16:46.543+0000] {logging_mixin.py:190} INFO - Finished 102/191: 0001193125-18-005021
[2025-05-13T17:16:46.544+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['fitusiran']}, {'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, {'name': 'ALN-TTRsc02', 'mechanism_of_action': 'a subcutaneously administered investigational RNAi therapeutic in clinical development', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2018-01-08', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.546+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.548+0000] {logging_mixin.py:190} INFO - Finished 103/191: 0001193125-17-000876
[2025-05-13T17:16:46.549+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.550+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.552+0000] {logging_mixin.py:190} INFO - Finished 104/191: 0001178670-21-000017
[2025-05-13T17:16:46.553+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.555+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.558+0000] {logging_mixin.py:190} INFO - Finished 105/191: 0001157523-16-007200
[2025-05-13T17:16:46.559+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.562+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.564+0000] {logging_mixin.py:190} INFO - Finished 106/191: 0001157523-17-000400
[2025-05-13T17:16:46.565+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.568+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'complement-mediated diseases']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.571+0000] {logging_mixin.py:190} INFO - Finished 107/191: 0001178670-22-000016
[2025-05-13T17:16:46.574+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:46.578+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'vutrisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis and Stargardt Disease', 'preclinical_data': [], 'clinical_trials': ['HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.'], 'upcoming_milestones': ['FDA review; extended PDUFA goal date of July 14, 2022.'], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}, {'name': 'zilebesiran (formerly ALN-AGT)', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'angiotensinogen', 'indication': 'hypertension', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, {'name': 'cemdisiran', 'mechanism_of_action': 'C5 small interfering RNA (siRNA)', 'target': 'C5 complement protein', 'indication': 'C5 complement-mediated diseases', 'preclinical_data': [], 'clinical_trials': ['Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'antithrombin', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.579+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.918000 seconds
[2025-05-13T17:16:46.581+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.584+0000] {logging_mixin.py:190} INFO - Finished 108/191: 0001178670-23-000011
[2025-05-13T17:16:46.584+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'polyneuropathy of hATTR amyloidosis in adults', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'PDUFA action date of October 8, 2023'], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly ALN-PCSsc']}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.589+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic'], 'indication': ['hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.597+0000] {logging_mixin.py:190} INFO - Finished 109/191: 0001193125-16-731590
[2025-05-13T17:16:46.598+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'revusiran', 'mechanism_of_action': 'RNA interference therapeutic', 'target': '', 'indication': 'hereditary ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.600+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.603+0000] {logging_mixin.py:190} INFO - Finished 110/191: 0001193125-16-713525
[2025-05-13T17:16:46.603+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.605+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.607+0000] {logging_mixin.py:190} INFO - Finished 111/191: 0001157523-16-006448
[2025-05-13T17:16:46.608+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.609+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.612+0000] {logging_mixin.py:190} INFO - Finished 112/191: 0001178670-22-000020
[2025-05-13T17:16:46.613+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.615+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.618+0000] {logging_mixin.py:190} INFO - Finished 113/191: 0001178670-20-000019
[2025-05-13T17:16:46.618+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': [], 'aliases': []}, {'name': 'nedosiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria (PH)', 'preclinical_data': [], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019'], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.620+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.622+0000] {logging_mixin.py:190} INFO - Finished 114/191: 0001193125-16-622502
[2025-05-13T17:16:46.623+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.625+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.627+0000] {logging_mixin.py:190} INFO - Finished 115/191: 0001178670-20-000007
[2025-05-13T17:16:46.627+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': 'lipid complex injection', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.629+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.631+0000] {logging_mixin.py:190} INFO - Finished 116/191: 0001193125-16-582064
[2025-05-13T17:16:46.631+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.633+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.635+0000] {logging_mixin.py:190} INFO - Finished 117/191: 0001178670-19-000005
[2025-05-13T17:16:46.636+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.638+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.641+0000] {logging_mixin.py:190} INFO - Finished 118/191: 0001157523-16-004564
[2025-05-13T17:16:46.643+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.645+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.648+0000] {logging_mixin.py:190} INFO - Finished 119/191: 0001157523-16-005377
[2025-05-13T17:16:46.649+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.651+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.654+0000] {logging_mixin.py:190} INFO - Finished 120/191: 0001193125-16-535555
[2025-05-13T17:16:46.656+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.658+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.661+0000] {logging_mixin.py:190} INFO - Finished 121/191: 0001193125-16-425799
[2025-05-13T17:16:46.663+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.666+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.669+0000] {logging_mixin.py:190} INFO - Finished 122/191: 0001193125-15-410845
[2025-05-13T17:16:46.670+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.672+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.674+0000] {logging_mixin.py:190} INFO - Finished 123/191: 0001193125-15-407792
[2025-05-13T17:16:46.675+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.676+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.678+0000] {logging_mixin.py:190} INFO - Finished 124/191: 0001157523-15-002821
[2025-05-13T17:16:46.679+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.680+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.682+0000] {logging_mixin.py:190} INFO - Finished 125/191: 0001193125-15-336652
[2025-05-13T17:16:46.683+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.684+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.687+0000] {logging_mixin.py:190} INFO - Finished 126/191: 0001157523-15-003798
[2025-05-13T17:16:46.688+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.689+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.691+0000] {logging_mixin.py:190} INFO - Finished 127/191: 0001178670-21-000024
[2025-05-13T17:16:46.692+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.693+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.696+0000] {logging_mixin.py:190} INFO - Finished 128/191: 0001193125-15-219361
[2025-05-13T17:16:46.697+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.698+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.700+0000] {logging_mixin.py:190} INFO - Finished 129/191: 0001193125-15-252425
[2025-05-13T17:16:46.700+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.702+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.704+0000] {logging_mixin.py:190} INFO - Finished 130/191: 0001178670-24-000008
[2025-05-13T17:16:46.706+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.707+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.709+0000] {logging_mixin.py:190} INFO - Finished 131/191: 0001193125-15-250381
[2025-05-13T17:16:46.710+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.711+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': []}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.713+0000] {logging_mixin.py:190} INFO - Finished 132/191: 0001178670-23-000005
[2025-05-13T17:16:46.714+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'TTR protein', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['ONPATTRO']}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'GAPDH', 'indication': 'Primary Hyperoxaluria type 1 (PH1)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.715+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.719+0000] {logging_mixin.py:190} INFO - Finished 133/191: 0001193125-15-172191
[2025-05-13T17:16:46.720+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.722+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.724+0000] {logging_mixin.py:190} INFO - Finished 134/191: 0001157523-15-000553
[2025-05-13T17:16:46.724+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.726+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.728+0000] {logging_mixin.py:190} INFO - Finished 135/191: 0001193125-15-010741
[2025-05-13T17:16:46.728+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.730+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.732+0000] {logging_mixin.py:190} INFO - Finished 136/191: 0001193125-15-119442
[2025-05-13T17:16:46.732+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.733+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.736+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:46.736+0000] {logging_mixin.py:190} INFO - Finished 137/191: 0001193125-15-004485
[2025-05-13T17:16:46.738+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.753000 seconds
[2025-05-13T17:16:46.738+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.740+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.742+0000] {logging_mixin.py:190} INFO - Finished 138/191: 0001564590-19-015366
[2025-05-13T17:16:46.742+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'lumasiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'primary hyperoxaluria', 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.744+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.746+0000] {logging_mixin.py:190} INFO - Finished 139/191: 0001193125-15-020438
[2025-05-13T17:16:46.746+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.748+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.750+0000] {logging_mixin.py:190} INFO - Finished 140/191: 0001157523-15-001675
[2025-05-13T17:16:46.751+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.752+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.754+0000] {logging_mixin.py:190} INFO - Finished 141/191: 0001193125-14-447755
[2025-05-13T17:16:46.755+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.757+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.759+0000] {logging_mixin.py:190} INFO - Finished 142/191: 0001193125-14-446129
[2025-05-13T17:16:46.759+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.761+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.763+0000] {logging_mixin.py:190} INFO - Finished 143/191: 0001564590-18-018696
[2025-05-13T17:16:46.764+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.765+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.767+0000] {logging_mixin.py:190} INFO - Finished 144/191: 0001193125-15-031716
[2025-05-13T17:16:46.767+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.769+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.771+0000] {logging_mixin.py:190} INFO - Finished 145/191: 0001157523-14-004401
[2025-05-13T17:16:46.772+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.773+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.776+0000] {logging_mixin.py:190} INFO - Finished 146/191: 0001193125-14-258369
[2025-05-13T17:16:46.776+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.778+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.781+0000] {logging_mixin.py:190} INFO - Finished 147/191: 0001193125-14-128105
[2025-05-13T17:16:46.782+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.783+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.786+0000] {logging_mixin.py:190} INFO - Finished 148/191: 0001157523-14-003397
[2025-05-13T17:16:46.793+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.802+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.806+0000] {logging_mixin.py:190} INFO - Finished 149/191: 0001193125-14-112393
[2025-05-13T17:16:46.808+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.811+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.814+0000] {logging_mixin.py:190} INFO - Finished 150/191: 0001157523-14-000620
[2025-05-13T17:16:46.815+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.816+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.819+0000] {logging_mixin.py:190} INFO - Finished 151/191: 0001193125-14-085635
[2025-05-13T17:16:46.820+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.821+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.824+0000] {logging_mixin.py:190} INFO - Finished 152/191: 0001193125-14-354903
[2025-05-13T17:16:46.825+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.827+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.829+0000] {logging_mixin.py:190} INFO - Finished 153/191: 0001157523-14-002039
[2025-05-13T17:16:46.830+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.832+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.835+0000] {logging_mixin.py:190} INFO - Finished 154/191: 0001178670-25-000026
[2025-05-13T17:16:46.836+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.839+0000] {logging_mixin.py:190} INFO - Finished 155/191: 0001564590-19-029367
[2025-05-13T17:16:46.839+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.841+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.843+0000] {logging_mixin.py:190} INFO - Finished 156/191: 0001193125-14-073378
[2025-05-13T17:16:46.843+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.845+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.848+0000] {logging_mixin.py:190} INFO - Finished 157/191: 0001564590-17-022281
[2025-05-13T17:16:46.848+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.850+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.853+0000] {logging_mixin.py:190} INFO - Finished 158/191: 0001193125-14-068393
[2025-05-13T17:16:46.854+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.856+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.857+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2015/ALNY_10-Q_2015-11-09_0001193125-15-371063.txt
[2025-05-13T17:16:46.864+0000] {logging_mixin.py:190} INFO - Finished 159/191: 0001193125-16-758802
[2025-05-13T17:16:46.865+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.867+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.870+0000] {logging_mixin.py:190} INFO - Finished 160/191: 0001564590-18-028070
[2025-05-13T17:16:46.871+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.873+0000] {logging_mixin.py:190} INFO - Finished 161/191: 0001193125-16-671945
[2025-05-13T17:16:46.874+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017'], 'upcoming_milestones': [], 'references': ['ITEM 5, August 2, 2016 SEC Filing'], 'aliases': []}]}
[2025-05-13T17:16:46.875+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}}}
[2025-05-13T17:16:46.878+0000] {logging_mixin.py:190} INFO - Finished 162/191: 0001564590-17-008948
[2025-05-13T17:16:46.878+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.879+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.882+0000] {logging_mixin.py:190} INFO - Finished 163/191: 0001193125-14-008836
[2025-05-13T17:16:46.882+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.884+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.886+0000] {logging_mixin.py:190} INFO - Finished 164/191: 0001178670-20-000015
[2025-05-13T17:16:46.887+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.888+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.891+0000] {logging_mixin.py:190} INFO - Finished 165/191: 0001157523-13-005351
[2025-05-13T17:16:46.892+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.893+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.895+0000] {logging_mixin.py:190} INFO - Finished 166/191: 0001193125-15-178432
[2025-05-13T17:16:46.896+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.897+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.899+0000] {logging_mixin.py:190} INFO - Finished 167/191: 0001157523-13-004008
[2025-05-13T17:16:46.900+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.901+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:46.903+0000] {logging_mixin.py:190} INFO - Finished 168/191: 0001193125-14-008903
[2025-05-13T17:16:46.903+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'transthyretin (TTR)', 'indication': 'TTR amyloid cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, {'name': 'ALN-AS1', 'mechanism_of_action': '', 'target': '', 'indication': 'hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Item 1.01', 'Filing Date: 2014-01-13', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}]}
[2025-05-13T17:16:46.905+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.907+0000] {logging_mixin.py:190} INFO - Finished 169/191: 0001564590-17-016993
[2025-05-13T17:16:46.908+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.910+0000] {logging_mixin.py:190} INFO - Finished 170/191: 0001157523-13-002380
[2025-05-13T17:16:46.911+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.913+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.915+0000] {logging_mixin.py:190} INFO - Finished 171/191: 0001193125-13-253522
[2025-05-13T17:16:46.916+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:46.917+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.919+0000] {logging_mixin.py:190} INFO - Finished 172/191: 0001193125-16-577773
[2025-05-13T17:16:46.920+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR-PN', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial, completed enrollment, data expected in 2017'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:46.921+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 3 study design aligned with FDA'], 'upcoming_milestones': [], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:46.923+0000] {logging_mixin.py:190} INFO - Finished 173/191: 0001564590-18-011031
[2025-05-13T17:16:46.925+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018'], 'upcoming_milestones': ['Regulatory approval in the U.S. and EU'], 'references': ['SEC filing details, November 2017'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': '', 'target': '', 'indication': 'AIP', 'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['SEC filing details, April 2018'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': ['Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE'], 'upcoming_milestones': ['Resumption of dosing in clinical studies'], 'references': ['SEC filing details, September 2017'], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'hATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension'], 'upcoming_milestones': [], 'references': ['SEC filing details, October 2016'], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': 'advanced pancreatic neuroendocrine cancer', 'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient'], 'upcoming_milestones': [], 'references': ['SEC filing details'], 'aliases': []}]}
[2025-05-13T17:16:46.927+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient'], 'upcoming_milestones': [], 'references': ['SEC filing details'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:47.001+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:47.002+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.503000 seconds
[2025-05-13T17:16:47.040+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2013/ALNY_10-Q_2013-08-09_0001193125-13-328105.txt
[2025-05-13T17:16:47.114+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2015/ALNY_10-Q_2015-08-07_0001193125-15-282067.txt
[2025-05-13T17:16:47.415+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-371063
[2025-05-13T17:16:47.416+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.416+0000] {logging_mixin.py:190} INFO - Finished 174/191: 0001193125-15-371063
[2025-05-13T17:16:47.417+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.418+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['SEC filing details'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}}}
[2025-05-13T17:16:47.540+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-13-328105
[2025-05-13T17:16:47.541+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-PCS', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.542+0000] {logging_mixin.py:190} INFO - Finished 175/191: 0001193125-13-328105
[2025-05-13T17:16:47.543+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-PCS', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.544+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['SEC filing details'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:47.634+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-282067
[2025-05-13T17:16:47.635+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.636+0000] {logging_mixin.py:190} INFO - Finished 176/191: 0001193125-15-282067
[2025-05-13T17:16:47.637+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:47.638+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['SEC filing details'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:48.261+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:48.263+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.254000 seconds
[2025-05-13T17:16:49.598+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:49.599+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 168764, Requested 51021. Please try again in 5.935s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:49.599+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:16:49.840+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:49.841+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.109000 seconds
[2025-05-13T17:16:54.095+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:54.097+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.344000 seconds
[2025-05-13T17:16:54.210+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:54.211+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 10.232000 seconds
[2025-05-13T17:16:54.621+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:54.622+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 9.902000 seconds
[2025-05-13T17:16:55.136+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:55.137+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.742000 seconds
[2025-05-13T17:16:55.735+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:55.736+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.702000 seconds
[2025-05-13T17:16:55.823+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:55.825+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.617000 seconds
[2025-05-13T17:16:55.962+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:55.963+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 177363, Requested 50965. Please try again in 8.498s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:55.964+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:56.077+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:56.079+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 176967, Requested 50957. Please try again in 8.377s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:56.080+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:56.594+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:56.693+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:56.695+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.211000 seconds
[2025-05-13T17:16:57.115+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:57.209+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2013/ALNY_10-Q_2013-11-07_0001193125-13-431609.txt
[2025-05-13T17:16:57.654+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2013/ALNY_10-Q_2013-05-07_0001193125-13-204676.txt
[2025-05-13T17:16:57.741+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-13-431609
[2025-05-13T17:16:57.742+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:16:57.743+0000] {logging_mixin.py:190} INFO - Finished 177/191: 0001193125-13-431609
[2025-05-13T17:16:57.743+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:16:57.746+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['SEC filing details'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:16:58.167+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-13-204676
[2025-05-13T17:16:58.168+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-PCS', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}]}
[2025-05-13T17:16:58.169+0000] {logging_mixin.py:190} INFO - Finished 178/191: 0001193125-13-204676
[2025-05-13T17:16:58.170+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-PCS', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}]}
[2025-05-13T17:16:58.172+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:16:58.414+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:16:58.977+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2014/ALNY_10-Q_2014-08-08_0001193125-14-301873.txt
[2025-05-13T17:16:59.426+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:59.429+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 174862, Requested 50930. Please try again in 7.737s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:59.432+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:59.454+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:59.456+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.685000 seconds
[2025-05-13T17:16:59.675+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:59.683+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 179855, Requested 50973. Please try again in 9.248s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:59.688+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:59.746+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:59.750+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 179591, Requested 51183. Please try again in 9.232s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:59.755+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:16:59.840+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:16:59.855+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 179413, Requested 50856. Please try again in 9.08s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:16:59.857+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:16:59.983+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-301873
[2025-05-13T17:16:59.984+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:59.986+0000] {logging_mixin.py:190} INFO - Finished 179/191: 0001193125-14-301873
[2025-05-13T17:16:59.988+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:16:59.993+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:00.213+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:00.214+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.102000 seconds
[2025-05-13T17:17:00.911+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:01.625+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:01.664+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2021/ALNY_10-K_2021-02-11_0001178670-21-000010.txt
[2025-05-13T17:17:01.696+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:02.184+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2014/ALNY_10-Q_2014-05-09_0001193125-14-192579.txt
[2025-05-13T17:17:02.205+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-21-000010
[2025-05-13T17:17:02.206+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:17:02.206+0000] {logging_mixin.py:190} INFO - Finished 180/191: 0001178670-21-000010
[2025-05-13T17:17:02.207+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:17:02.223+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:02.258+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2014/ALNY_10-Q_2014-11-06_0001193125-14-399866.txt
[2025-05-13T17:17:02.727+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-192579
[2025-05-13T17:17:02.729+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:17:02.730+0000] {logging_mixin.py:190} INFO - Finished 181/191: 0001193125-14-192579
[2025-05-13T17:17:02.731+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-VSP', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:17:02.733+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:02.855+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-399866
[2025-05-13T17:17:02.856+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:17:02.857+0000] {logging_mixin.py:190} INFO - Finished 182/191: 0001193125-14-399866
[2025-05-13T17:17:02.859+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR patients suffering from FAP', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:17:02.862+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:04.084+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:04.088+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 177787, Requested 49052. Please try again in 8.051s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:04.091+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:17:04.746+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:04.748+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175638, Requested 50886. Please try again in 7.957s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:04.754+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:17:04.816+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:04.818+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175390, Requested 50892. Please try again in 7.884s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:04.818+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:17:04.852+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:04.856+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175320, Requested 50888. Please try again in 7.862s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:04.862+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:17:04.883+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:04.886+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 175174, Requested 51198. Please try again in 7.911s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:04.888+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:17:05.033+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:05.035+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 178073, Requested 50860. Please try again in 8.679s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:05.037+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:05.089+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:05.095+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.636000 seconds
[2025-05-13T17:17:05.095+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2020/ALNY_10-K_2020-02-13_0001178670-20-000004.txt
[2025-05-13T17:17:05.081+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:05.118+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 8.658000 seconds
[2025-05-13T17:17:05.347+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:05.585+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:05.593+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.505000 seconds
[2025-05-13T17:17:05.843+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-20-000004
[2025-05-13T17:17:05.845+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:17:05.851+0000] {logging_mixin.py:190} INFO - Finished 183/191: 0001178670-20-000004
[2025-05-13T17:17:05.857+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:17:05.863+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:06.411+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2022/ALNY_10-K_2022-02-10_0001178670-22-000013.txt
[2025-05-13T17:17:06.882+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-22-000013
[2025-05-13T17:17:06.882+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:17:06.883+0000] {logging_mixin.py:190} INFO - Finished 184/191: 0001178670-22-000013
[2025-05-13T17:17:06.884+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:17:06.887+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:07.410+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:07.412+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 190754, Requested 50885. Please try again in 12.491s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:07.413+0000] {logging_mixin.py:190} INFO - [Chunk 1] LLM response missing or failed.
[2025-05-13T17:17:07.557+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:07.558+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.311000 seconds
[2025-05-13T17:17:10.104+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:10.106+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 181703, Requested 50862. Please try again in 9.769s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:10.109+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:10.160+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:10.300+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:10.301+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 7.644000 seconds
[2025-05-13T17:17:10.613+0000] {logging_mixin.py:190} INFO - Failed to upload 10-K filing to GCS: ALNY/10-K/2019/ALNY_10-K_2019-02-14_0001564590-19-003022.txt
[2025-05-13T17:17:10.614+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-19-003022
[2025-05-13T17:17:10.615+0000] {logging_mixin.py:190} INFO - 594 False
[2025-05-13T17:17:10.616+0000] {logging_mixin.py:190} INFO - Finished 185/191: 0001564590-19-003022
[2025-05-13T17:17:10.618+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:12.503+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:12.504+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 6.679000 seconds
[2025-05-13T17:17:13.906+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:13.908+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.265000 seconds
[2025-05-13T17:17:13.966+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:13.968+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 5.211000 seconds
[2025-05-13T17:17:19.557+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.559+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 194670, Requested 50879. Please try again in 13.664s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:19.559+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:19.579+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.581+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 194535, Requested 50874. Please try again in 13.622s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:19.581+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:19.603+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.604+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 194478, Requested 50872. Please try again in 13.605s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:19.605+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:19.767+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.767+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.828000 seconds
[2025-05-13T17:17:19.783+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.783+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.265000 seconds
[2025-05-13T17:17:19.816+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:19.818+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.419000 seconds
[2025-05-13T17:17:20.073+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:20.074+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 13.150000 seconds
[2025-05-13T17:17:20.462+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:20.463+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.786000 seconds
[2025-05-13T17:17:33.362+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:33.366+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.319000 seconds
[2025-05-13T17:17:33.604+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:33.607+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.264000 seconds
[2025-05-13T17:17:33.643+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:33.645+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 196491, Requested 50959. Please try again in 14.235s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:33.647+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:17:33.676+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:33.681+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 196377, Requested 50883. Please try again in 14.178s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:33.686+0000] {logging_mixin.py:190} INFO - [Chunk 2] LLM response missing or failed.
[2025-05-13T17:17:34.060+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:34.072+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 14.372000 seconds
[2025-05-13T17:17:34.073+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:35.110+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:35.232+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2018/ALNY_10-K_2018-02-15_0001564590-18-002152.txt
[2025-05-13T17:17:35.869+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-18-002152
[2025-05-13T17:17:35.873+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:17:35.885+0000] {logging_mixin.py:190} INFO - Finished 186/191: 0001564590-18-002152
[2025-05-13T17:17:35.892+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:17:35.914+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': []}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}}}
[2025-05-13T17:17:35.949+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2017/ALNY_10-K_2017-02-15_0001564590-17-001649.txt
[2025-05-13T17:17:36.492+0000] {logging_mixin.py:190} INFO - Finished processing: 0001564590-17-001649
[2025-05-13T17:17:36.495+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'hereditary ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'APOLLO Phase 3 trial; ongoing'], 'upcoming_milestones': ['Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'hereditary ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial; ENDEAVOUR study; discontinued'], 'upcoming_milestones': [], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'inclisiran (formerly ALN-PCSsc)', 'mechanism_of_action': 'RNA interference targeting PCSK9', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNA interference', 'target': 'antithrombin', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial; endpoints: safety, efficacy; ongoing'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': 'RNA interference', 'target': 'aminolevulinic acid synthase 1 (ALAS1)', 'indication': 'hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: ongoing'], 'upcoming_milestones': [], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}]}
[2025-05-13T17:17:36.499+0000] {logging_mixin.py:190} INFO - Finished 187/191: 0001564590-17-001649
[2025-05-13T17:17:36.501+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'hereditary ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'APOLLO Phase 3 trial; ongoing'], 'upcoming_milestones': ['Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'revusiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'hereditary ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial; ENDEAVOUR study; discontinued'], 'upcoming_milestones': [], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'inclisiran (formerly ALN-PCSsc)', 'mechanism_of_action': 'RNA interference targeting PCSK9', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': 'RNA interference', 'target': 'antithrombin', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial; endpoints: safety, efficacy; ongoing'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial'], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}, {'name': 'givosiran', 'mechanism_of_action': 'RNA interference', 'target': 'aminolevulinic acid synthase 1 (ALAS1)', 'indication': 'hepatic porphyrias', 'preclinical_data': [], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: ongoing'], 'upcoming_milestones': [], 'references': ['Item 3, SEC Filing, 2016', 'Item 3, SEC Filing, 2015'], 'aliases': []}]}
[2025-05-13T17:17:36.509+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'hereditary ATTR amyloidosis', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3 trial; ongoing', 'APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval', 'PDUFA action date not specified', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors', 'hemophilia and other rare bleeding disorders'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Phase 3 trial; endpoints: safety, efficacy; ongoing', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial', 'Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 1 trial; endpoints: safety, efficacy; results: ongoing', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias', 'hepatic porphyrias'], 'target': ['aminolevulinic acid synthase 1 (ALAS1)']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 study', 'Phase 3 trial; ENDEAVOUR study; discontinued', 'discontinued development'], 'upcoming_milestones': [], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016'], 'aliases': [], 'target': ['transthyretin (TTR)']}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, 'inclisiran (formerly ALN-PCSsc)': {'mechanism_of_action': ['RNA interference targeting PCSK9'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016'], 'aliases': []}}}
[2025-05-13T17:17:45.065+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:47.225+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2015/ALNY_10-K_2015-02-13_0001193125-15-050223.txt
[2025-05-13T17:17:48.040+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-15-050223
[2025-05-13T17:17:48.043+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': ['ALN-TTRsc02']}, {'name': 'revusiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': 'RNA interference', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': 'RNA interference', 'target': 'antithrombin', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}]}
[2025-05-13T17:17:48.048+0000] {logging_mixin.py:190} INFO - Finished 188/191: 0001193125-15-050223
[2025-05-13T17:17:48.051+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'patisiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': ['ALN-TTRsc02']}, {'name': 'revusiran', 'mechanism_of_action': 'RNA interference', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': ['Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': 'RNA interference', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': 'RNA interference', 'target': 'antithrombin', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Significant Agreements, SEC Filing', 'Item 3, 2014'], 'aliases': []}]}
[2025-05-13T17:17:48.060+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'hereditary ATTR amyloidosis', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3 trial; ongoing', 'APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval', 'PDUFA action date not specified', 'Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ALN-TTRsc02', 'ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors', 'hemophilia and other rare bleeding disorders'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Phase 3 trial; endpoints: safety, efficacy; ongoing', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial', 'Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 3, 2014', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders'], 'mechanism_of_action': ['RNA interference'], 'target': ['antithrombin']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 1 trial; endpoints: safety, efficacy; results: ongoing', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias', 'hepatic porphyrias'], 'target': ['aminolevulinic acid synthase 1 (ALAS1)']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.', 'Phase 3 study', 'Phase 3 trial; ENDEAVOUR study; discontinued', 'discontinued development'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016', 'Significant Agreements, SEC Filing'], 'aliases': [], 'target': ['transthyretin (TTR)']}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, 'inclisiran (formerly ALN-PCSsc)': {'mechanism_of_action': ['RNA interference targeting PCSK9'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016'], 'aliases': []}, 'ALN-PCSsc': {'mechanism_of_action': ['RNA interference'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Item 3, 2014', 'Significant Agreements, SEC Filing'], 'aliases': []}}}
[2025-05-13T17:17:48.327+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:48.330+0000] {logging_mixin.py:190} INFO - OpenAI API call failed: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-DrJA6EhxcamxWcrd61odhGBX on tokens per min (TPM): Limit 200000, Used 187287, Requested 50957. Please try again in 11.473s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}
[2025-05-13T17:17:48.333+0000] {logging_mixin.py:190} INFO - [Chunk 3] LLM response missing or failed.
[2025-05-13T17:17:48.759+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
[2025-05-13T17:17:48.763+0000] {_base_client.py:1085} INFO - Retrying request to /chat/completions in 12.352000 seconds
[2025-05-13T17:17:48.844+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:17:49.596+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2016/ALNY_10-K_2016-02-12_0001193125-16-462538.txt
[2025-05-13T17:17:50.554+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-16-462538
[2025-05-13T17:17:50.555+0000] {logging_mixin.py:190} INFO - 594 {'programs': []}
[2025-05-13T17:17:50.556+0000] {logging_mixin.py:190} INFO - Finished 189/191: 0001193125-16-462538
[2025-05-13T17:17:50.558+0000] {logging_mixin.py:190} INFO - 609 {'programs': []}
[2025-05-13T17:17:50.568+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'hereditary ATTR amyloidosis', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3 trial; ongoing', 'APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval', 'PDUFA action date not specified', 'Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ALN-TTRsc02', 'ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors', 'hemophilia and other rare bleeding disorders'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Phase 3 trial; endpoints: safety, efficacy; ongoing', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial', 'Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 3, 2014', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders'], 'mechanism_of_action': ['RNA interference'], 'target': ['antithrombin']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 1 trial; endpoints: safety, efficacy; results: ongoing', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias', 'hepatic porphyrias'], 'target': ['aminolevulinic acid synthase 1 (ALAS1)']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.', 'Phase 3 study', 'Phase 3 trial; ENDEAVOUR study; discontinued', 'discontinued development'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016', 'Significant Agreements, SEC Filing'], 'aliases': [], 'target': ['transthyretin (TTR)']}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, 'inclisiran (formerly ALN-PCSsc)': {'mechanism_of_action': ['RNA interference targeting PCSK9'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016'], 'aliases': []}, 'ALN-PCSsc': {'mechanism_of_action': ['RNA interference'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Item 3, 2014', 'Significant Agreements, SEC Filing'], 'aliases': []}}}
[2025-05-13T17:17:59.465+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:18:00.423+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2013/ALNY_10-K_2013-02-19_0001193125-13-065475.txt
[2025-05-13T17:18:00.983+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-13-065475
[2025-05-13T17:18:00.987+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCS02', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Completed a Phase I clinical trial'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Currently in pre-clinical development'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, {'name': 'ALN-RSV01', 'mechanism_of_action': '', 'target': 'respiratory syncytial virus (RSV)', 'indication': 'respiratory syncytial virus infection', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:18:00.988+0000] {logging_mixin.py:190} INFO - Finished 190/191: 0001193125-13-065475
[2025-05-13T17:18:00.991+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ALN-TTR02', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-TTRsc', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'transthyretin-mediated amyloidosis (ATTR)', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCS02', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Completed a Phase I clinical trial'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': 'RNAi therapeutic', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Currently in pre-clinical development'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, {'name': 'ALN-RSV01', 'mechanism_of_action': '', 'target': 'respiratory syncytial virus (RSV)', 'indication': 'respiratory syncytial virus infection', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:18:00.995+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'hereditary ATTR amyloidosis', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3 trial; ongoing', 'APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['FDA sNDA resubmission', 'Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval', 'PDUFA action date not specified', 'Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ALN-TTRsc02', 'ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors', 'hemophilia and other rare bleeding disorders'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Phase 3 trial; endpoints: safety, efficacy; ongoing', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial', 'Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 3, 2014', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders'], 'mechanism_of_action': ['RNA interference'], 'target': ['antithrombin']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 1 trial; endpoints: safety, efficacy; results: ongoing', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias', 'hepatic porphyrias'], 'target': ['aminolevulinic acid synthase 1 (ALAS1)']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.', 'Phase 3 study', 'Phase 3 trial; ENDEAVOUR study; discontinued', 'discontinued development'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016', 'Significant Agreements, SEC Filing'], 'aliases': [], 'target': ['transthyretin (TTR)']}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran'], 'target': ['transthyretin (TTR)'], 'indication': ['transthyretin-mediated amyloidosis (ATTR)']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, 'inclisiran (formerly ALN-PCSsc)': {'mechanism_of_action': ['RNA interference targeting PCSK9'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016'], 'aliases': []}, 'ALN-PCSsc': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Currently in pre-clinical development', 'Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million', 'Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Item 3, 2014', 'Significant Agreements, SEC Filing'], 'aliases': []}, 'ALN-PCS02': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Completed a Phase I clinical trial'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, 'ALN-RSV01': {'target': ['respiratory syncytial virus (RSV)'], 'indication': ['respiratory syncytial virus infection'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:18:13.317+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:18:15.449+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:18:16.386+0000] {logging_mixin.py:190} INFO - Uploaded 10-K filing to GCS: gs://clinical_data_may25/ALNY/10-K/2014/ALNY_10-K_2014-02-20_0001193125-14-060913.txt
[2025-05-13T17:18:16.999+0000] {logging_mixin.py:190} INFO - Finished processing: 0001193125-14-060913
[2025-05-13T17:18:17.007+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'ALN-RSV01', 'mechanism_of_action': '', 'target': '', 'indication': 'RSV infection', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial completed'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-RSV02', 'mechanism_of_action': '', 'target': '', 'indication': 'pediatric patients', 'preclinical_data': [], 'clinical_trials': ['Development on hold as of December 2010'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial completed', 'Phase 3 trial initiation in 2013'], 'upcoming_milestones': ['Completion of Phase 3 clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCS02', 'mechanism_of_action': '', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial completed'], 'upcoming_milestones': ['Initiation of ALN-PCSsc Phase 1 clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': '', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-TTR', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['ALN-TTRsc']}]}
[2025-05-13T17:18:17.011+0000] {logging_mixin.py:190} INFO - Finished 191/191: 0001193125-14-060913
[2025-05-13T17:18:17.012+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'ALN-RSV01', 'mechanism_of_action': '', 'target': '', 'indication': 'RSV infection', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial completed'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-RSV02', 'mechanism_of_action': '', 'target': '', 'indication': 'pediatric patients', 'preclinical_data': [], 'clinical_trials': ['Development on hold as of December 2010'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial completed', 'Phase 3 trial initiation in 2013'], 'upcoming_milestones': ['Completion of Phase 3 clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCS02', 'mechanism_of_action': '', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial completed'], 'upcoming_milestones': ['Initiation of ALN-PCSsc Phase 1 clinical trial'], 'references': [], 'aliases': []}, {'name': 'ALN-PCSsc', 'mechanism_of_action': '', 'target': 'PCSK9', 'indication': 'hypercholesterolemia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-TTR', 'mechanism_of_action': '', 'target': 'transthyretin (TTR)', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ALN-AT3', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia and other rare bleeding disorders', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['ALN-TTRsc']}]}
[2025-05-13T17:18:17.014+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'patisiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['TTR protein', 'transthyretin', 'transthyretin (TTR)'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis patients suffering from FAP', 'ATTR amyloidosis with cardiomyopathy', 'ATTR patients suffering from FAP', 'cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis', 'hATTR amyloidosis', 'hATTR-PN', 'hereditary ATTR amyloidosis', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['APOLLO Phase 3 trial; ongoing', 'APOLLO Phase 3, positive complete results reported in November 2017, NDA and MAA filed in December 2017, EMA accepted MAA in January 2018, FDA accepted NDA for priority review with action date of August 11, 2018', 'APOLLO-B Phase 3', 'APOLLO-B Phase 3, 12 months results, FDA CRL issued October 2023', 'APOLLO-B Phase 3, positive safety and efficacy results reported in August and September 2022', 'FDA issued a complete response letter in October 2023', 'Phase 2 trial completed', 'Phase 2 trial; endpoints: safety, efficacy, pharmacodynamics; results: successful completion of Phase 2 trial', 'Phase 3 clinical trial initiated in 2014; milestone payment of $7.0 million earned for completion of Phase 2 trial.', 'Phase 3 clinical trial, completed enrollment, data expected in 2017', 'Phase 3 clinical trial, completed enrollment, top-line data expected in mid-2017', 'Phase 3 clinical trial, ongoing, enrollment completed, data expected to report in 2017', 'Phase 3 clinical trial, ongoing, enrollment completed, expected data readout in 2017', 'Phase 3 trial initiation in 2013', 'Phase III clinical trial for Familial Amyloidotic Polyneuropathy'], 'upcoming_milestones': ['Completion of Phase 3 clinical trial', 'FDA sNDA resubmission', 'Next milestone payment from Sanofi Genzyme upon achievement of specified events in connection with a regulatory filing or approval', 'PDUFA action date not specified', 'Potential milestone payments ranging from $5.0 million to $20.0 million based on regulatory filing or approval events.', 'Regulatory approval in the U.S. and EU'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', 'FILING DATE: 2018-04-03', 'FILING DATE: 2023-10-10', 'Filing Date: 2014-01-13', 'Filing Date: 2024-08-01', 'ITEM 5, August 2, 2016 SEC Filing', 'Item 1.01', 'Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 5', 'Item 8.01', 'SEC filing details, November 2017', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518106272/d562624d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523253084/d279887d8k.htm'], 'aliases': ['ALN-TTRsc', 'ALN-TTRsc02', 'ONPATTRO']}, 'ONPATTRO': {'indication': ['hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hATTR amyloidosis in adults', 'polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults', 'the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults', 'FDA approved for the treatment of the polyneuropathy of hATTR amyloidosis in adults (August 2018)', 'Phase 3 study'], 'upcoming_milestones': ['FDA sNDA accepted for filing', 'Meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 13, 2023', 'PDUFA action date of October 8, 2023', 'sNDA submission for ONPATTRO as a potential treatment for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'FILING DATE: 2020-01-13', 'Filing Date: 2018-08-10', 'Filing Date: 2018-12-10', 'Filing Date: 2019-01-07', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2021-04-12', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing date: 2023-06-30', 'Item 1.01', 'Item 2.02', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518245969/d592861d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519003205/d676111d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521113304/d166405d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523179631/d442654d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['patisiran'], 'mechanism_of_action': ['RNAi therapeutic', 'lipid complex injection']}, 'zilebesiran': {'mechanism_of_action': ['siRNA therapeutic targeting liver-expressed angiotensinogen'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': ['Positive interim data from Phase 1 study reported in November 2021'], 'clinical_trials': ['KARDIA-1 Phase 2 study as a monotherapy', 'KARDIA-2 Phase 2 study as concomitant therapy'], 'upcoming_milestones': ['Completion of technology transfer of the manufacturing process prior to first commercial sale'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2023-07-26', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm'], 'aliases': []}, 'AMVUTTRA': {'preclinical_data': [], 'clinical_trials': ['HELIOS-B Phase 3 clinical trial for ATTR amyloidosis with cardiomyopathy, topline results expected in early 2024', 'Phase 3 for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy'], 'upcoming_milestones': ['sNDA submission for ONPATTRO for ATTR amyloidosis with cardiomyopathy in late 2022'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2022-06-14', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522173444/d518443d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['vutrisiran'], 'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin'], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'hATTR amyloidosis', 'hATTR amyloidosis with polyneuropathy', 'polyneuropathy of hereditary transthyretin-mediated amyloidosis']}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2019-11-20', 'FILING DATE: 2020-01-13', 'Filing Date: 2020-04-13', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 1.01', 'Item 2.02', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519296636/d834366d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520005791/d867754d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['givosiran'], 'indication': ['AHP', 'acute hepatic porphyria', 'acute hepatic porphyria (AHP)'], 'mechanism_of_action': ['RNAi therapeutic']}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Regulatory filings pending or planned in additional countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2021-01-11', 'Filing Date: 2023-01-09', 'Filing Date: 2024-01-08', 'Filing Date: 2024-08-01', 'Item 2.02', 'Item 5', 'SEC filing, date not provided', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312521005849/d105171d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm'], 'aliases': ['lumasiran'], 'indication': ['PH1', 'Primary Hyperoxaluria type 1 (PH1)', 'primary hyperoxaluria', 'primary hyperoxaluria type 1', 'primary hyperoxaluria type 1 (PH1)'], 'mechanism_of_action': ['RNAi therapeutic', 'RNAi therapeutic targeting LPHN1'], 'target': ['GAPDH', 'LPHN1']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': ['FDA action date set for April 14, 2022', 'HELIOS-A Phase 3 study in hATTR amyloidosis patients with polyneuropathy; positive results for 18-month endpoints and safety reported.', 'HELIOS-A Phase 3 study, positive topline results, January 2021', 'HELIOS-B Phase 3', 'HELIOS-B Phase 3, investigating cardiac manifestations, results pending', 'HELIOS-B Phase 3, positive topline results reported', 'NDA submitted to FDA in April 2021, accepted by FDA', 'Phase 3 HELIOS-B trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Presented additional 9-month data from HELIOS-A in September 2021', 'Reported positive topline results for 18-month endpoints and safety from HELIOS-A in October 2021', 'Submitted MAA in EU with EMA in September 2021'], 'upcoming_milestones': ['FDA review timeline extended by 3 months, new action date July 14, 2022', 'FDA review; extended PDUFA goal date of July 14, 2022.', 'Regulatory approval for broader indication', 'Regulatory approval in specified countries'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Filing Date: 2022-04-04', 'Filing Date: 2024-08-01', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm', 'Item 5', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867024000041/alny-20240630.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm'], 'aliases': [], 'indication': ['ATTR amyloidosis', 'ATTR amyloidosis and Stargardt Disease', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-cardiomyopathy'], 'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNAi therapeutic', 'RNAi therapeutic targeting TTR'], 'target': ['transthyretin (TTR)']}, 'ALN-AGT': {'preclinical_data': [], 'clinical_trials': ['Phase 2 trial, size not specified, endpoints not specified, dates not specified, results not specified', 'Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Regulatory approval in specified countries'], 'references': ['Item 1.01, Filing Date: 2020-08-20, URL: https://www.sec.gov/Archives/edgar/data/1178670/000119312520225661/d58239d8k.htm'], 'aliases': []}, 'fitusiran': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic', 'RNAi therapeutic targeting antithrombin'], 'target': ['antithrombin'], 'indication': ['Hemophilia', 'hemophilia', 'hemophilia A and B with or without inhibitors', 'hemophilia and other rare bleeding disorders'], 'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3, results pending', 'Phase 2 OLE study, ATLAS Phase 3 program, temporarily suspended in September 2017 due to thrombotic SAE', 'Phase 2 OLE study, temporary suspension of dosing in September 2017', 'Phase 2 open label extension study, ongoing, safety event reported, dosing suspended', 'Phase 3 study', 'Phase 3 trial; endpoints: safety, efficacy; ongoing', 'Potential filing date moved to 2024', 'Voluntary pause of dosing in October 2020 due to reports of thrombotic events', 'temporarily suspended dosing pending further review'], 'upcoming_milestones': ['Next milestone payment upon initiation of first global Phase 3 clinical trial', 'Resumption of dosing in clinical studies', 'development of a risk mitigation strategy', 'further review of the safety event'], 'references': ['10-Q Filing, Item 5, Filing Date: 2024-05-02, URL: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000023/alny-20240331.htm', '10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', '2017-09-07', 'Filing Date: 2018-12-10', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, September 2017', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'mivelsiran': {'indication': ['Alzheimer’s Disease'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Approval in more than 60 countries'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2020-04-13', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520105270/d900125d8k.htm'], 'aliases': ['Leqvio', 'formerly ALN-PCSsc'], 'indication': ['hypercholesterolemia']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'inotersen': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['adult hATTR amyloidosis patients with stage 1 or stage 2 polyneuropathy', 'stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'WAINUA': {'mechanism_of_action': ['antisense drug'], 'target': ['specific genes'], 'indication': ['not specified'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'lumasiran': {'mechanism_of_action': ['RNA interference targeting glycolate oxidase', 'RNAi therapeutic'], 'target': ['glycolate oxidase'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH1)', 'primary hyperoxaluria type 1'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 studies'], 'upcoming_milestones': ['Registration for the treatment of PH1'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'ALN-AAT02': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': ['Completion of Phase 3 development', 'Opportunity to opt-in to commercialize in countries outside the U.S.'], 'references': ['Filing Date: 2018-12-10', 'Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'DCR-A1AT': {'mechanism_of_action': ['RNA interference'], 'indication': ['alpha-1 antitrypsin deficiency-associated liver disease'], 'preclinical_data': [], 'clinical_trials': ['Phase 1/2'], 'upcoming_milestones': [], 'references': ['Filing Date: 2020-04-06', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312520099010/d910758d8k.htm'], 'aliases': []}, 'cemdisiran': {'preclinical_data': [], 'clinical_trials': ['Discontinued Phase 2 study due to recruitment challenges in November 2018', 'Phase 2 development', 'Phase 2 study as a monotherapy; Regeneron conducting Phase 3 study in combination with pozelimab.', 'Phase 2 study in patients with immunoglobulin A nephropathy'], 'upcoming_milestones': ['Negotiation of Co-Co Collaboration Agreement for combination product development', 'Plans for Phase 3 clinical development being finalized'], 'references': ['10-Q, 2022-10-27, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000026/alny-20220930.htm', 'Filing Date: 2018-12-10', 'Filing Date: 2019-04-09', 'Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm', 'Item 1.01', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': [], 'indication': ['Atypical hemolytic uremic syndrome', 'C5 complement-mediated diseases', 'complement-mediated diseases'], 'mechanism_of_action': ['C5 small interfering RNA (siRNA)'], 'target': ['C5 complement protein']}, 'ALN-AT3': {'preclinical_data': [], 'clinical_trials': ['ATLAS Phase 3 program', 'milestone payment of $50.0 million following the dosing of the first patient'], 'upcoming_milestones': ['Potential milestone payments upon completion of Human Proof-of-Principle Study.'], 'references': ['Filing Date: 2014-01-13', 'Filing Date: 2018-01-08', 'Filing Date: 2019-04-09', 'Item 1.01', 'Item 3, 2014', 'Significant Agreements, SEC Filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312519101737/d369023d8k.htm'], 'aliases': ['fitusiran'], 'indication': ['hemophilia and other rare bleeding disorders'], 'mechanism_of_action': ['RNA interference'], 'target': ['antithrombin']}, 'nedosiran': {'mechanism_of_action': ['RNAi therapeutic', 'once-monthly subcutaneous RNAi therapy'], 'indication': ['primary hyperoxaluria', 'primary hyperoxaluria (PH)', 'primary hyperoxaluria type 1 (PH1)'], 'preclinical_data': ['Positive topline results from PHYOX2 pivotal clinical trial (August 2021)'], 'clinical_trials': ['Phase 2 Part A, expected to complete enrollment of approximately 36 patients with PH1 and PH type 2 by the end of the fourth quarter of 2020', 'Phase 3, NDA submitted to FDA (September 2022)'], 'upcoming_milestones': ['Breakthrough Therapy Designation granted by FDA in July 2019', 'PDUFA action date of December 22, 2023'], 'references': ['SEC filing, date not provided'], 'aliases': ['RivflozaTM']}, 'givosiran': {'preclinical_data': [], 'clinical_trials': ['Phase 1 and Phase 1/2 OLE studies, results announced in April 2018', 'Phase 1 trial; endpoints: safety, efficacy; results: ongoing', 'Phase 3 study design aligned with FDA'], 'upcoming_milestones': ['Ongoing ENVISION Phase 3 study'], 'references': ['2017-09-07', 'Filing Date: 2018-12-10', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01', 'SEC filing details, April 2018', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312517278495/d434005d8k.htm', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': [], 'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'indication': ['AIP', 'acute hepatic porphyrias', 'hepatic porphyrias'], 'target': ['aminolevulinic acid synthase 1 (ALAS1)']}, 'ALN-HBV02': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-12-10', 'Item 8.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518346287/d525115d8k.htm'], 'aliases': []}, 'revusiran': {'mechanism_of_action': ['Investigational RNAi therapeutic', 'RNA interference', 'RNA interference therapeutic', 'RNAi therapeutic'], 'indication': ['hATTR amyloidosis', 'hereditary ATTR amyloidosis', 'hereditary ATTR amyloidosis with cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Discontinued development in October 2016, Phase 3 clinical trial ENDEAVOUR recommended for suspension', 'Discontinued due to recommendation from Data Monitoring Committee in October 2016', 'Phase 3 ENDEAVOUR study, suspended dosing', 'Phase 3 clinical trial initiated in 2014; milestone payment of $25.0 million earned for trial initiation.', 'Phase 3 study', 'Phase 3 trial; ENDEAVOUR study; discontinued', 'discontinued development'], 'upcoming_milestones': ['Potential milestone payments ranging from $5.0 million to $25.0 million based on regulatory approval events.'], 'references': ['Item 3, 2014', 'Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016', 'Item 8.01, Filing Date: 2016-10-05, https://www.sec.gov/Archives/edgar/data/1178670/000119312516731590/d253881d8k.htm', 'SEC filing details, October 2016', 'Significant Agreements, SEC Filing'], 'aliases': [], 'target': ['transthyretin (TTR)']}, 'eplontersen': {'indication': ['polyneuropathy of hATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, met co-primary and secondary endpoints, currently under regulatory review by the FDA, PDUFA action date December 22, 2023'], 'upcoming_milestones': ['Regulatory review by the FDA'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'acoramidis': {'mechanism_of_action': ['TTR stabilizer'], 'target': ['TTR'], 'indication': ['ATTR-CM'], 'preclinical_data': [], 'clinical_trials': ['Phase 3, announced positive results in July 2023, anticipating NDA filing with the FDA by the end of 2023'], 'upcoming_milestones': ['NDA filing with the FDA by the end of 2023'], 'references': ['SEC filing, date not provided'], 'aliases': []}, 'ALN-TTR02': {'preclinical_data': [], 'clinical_trials': ['Phase 2', 'Phase II'], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2018-01-08', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': ['patisiran'], 'target': ['transthyretin (TTR)'], 'indication': ['transthyretin-mediated amyloidosis (ATTR)']}, 'ALN-TTRsc02': {'mechanism_of_action': ['a subcutaneously administered investigational RNAi therapeutic in clinical development'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2018-01-08', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312518005021/d501805d8k.htm'], 'aliases': []}, 'zilebesiran (formerly ALN-AGT)': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['angiotensinogen'], 'indication': ['hypertension'], 'preclinical_data': [], 'clinical_trials': ['Phase 2 trial; funding for Phase 2 clinical trial committed by Blackstone upon meeting patient enrollment thresholds.'], 'upcoming_milestones': [], 'references': ['Form 10-Q, Filing Date: 2022-04-28, https://www.sec.gov/Archives/edgar/data/1178670/000117867022000016/alny-20220331.htm'], 'aliases': ['ALN-AGT']}, 'ALN-VSP': {'preclinical_data': [], 'clinical_trials': ['Clinical trial reported adverse event in one patient', 'Phase I'], 'upcoming_milestones': ['Expected arbitration decision in Q4 2015'], 'references': ['Filing Date: 2013-05-07', 'SEC filing details', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': [], 'indication': ['advanced pancreatic neuroendocrine cancer']}, 'ALN-TTRsc': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['transthyretin (TTR)'], 'indication': ['TTR amyloid cardiomyopathy', 'transthyretin-mediated amyloidosis (ATTR)'], 'preclinical_data': [], 'clinical_trials': ['Phase I', 'Phase II clinical trial'], 'upcoming_milestones': ['Potential milestone payment of $7.0 million based upon the completion of a successful Phase II ALN-TTR clinical trial'], 'references': ['Filing Date: 2013-05-07', 'Filing Date: 2014-01-13', 'Item 1.01', 'Section: PART II. ITEM 1A. RISK FACTORS', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-AS1': {'indication': ['hepatic porphyrias'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['Filing Date: 2014-01-13', 'Item 1.01', 'https://www.sec.gov/Archives/edgar/data/1178670/000119312514008903/d659671d8k.htm'], 'aliases': []}, 'ALN-PCS': {'preclinical_data': [], 'clinical_trials': ['Phase I'], 'upcoming_milestones': [], 'references': ['Filing Date: 2013-05-07', 'Section: PART II. ITEM 1A. RISK FACTORS'], 'aliases': []}, 'inclisiran (formerly ALN-PCSsc)': {'mechanism_of_action': ['RNA interference targeting PCSK9'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': ['Phase 1 trial; successful initiation of trial; 2014'], 'clinical_trials': ['Phase 1 trial; endpoints: safety, efficacy; results: successful completion'], 'upcoming_milestones': ['Next milestone payment from MDCO upon initiation of pivotal study'], 'references': ['Item 3, SEC Filing, 2015', 'Item 3, SEC Filing, 2016'], 'aliases': []}, 'ALN-PCSsc': {'mechanism_of_action': ['RNA interference', 'RNAi therapeutic'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Currently in pre-clinical development', 'Phase 1 clinical trial initiated in December 2014; milestone payment of $10.0 million earned for trial initiation.'], 'upcoming_milestones': ['Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million', 'Potential milestone payment of $20.0 million based upon the initiation of a pivotal study.'], 'references': ['Item 3, 2014', 'Significant Agreements, SEC Filing'], 'aliases': []}, 'ALN-PCS02': {'mechanism_of_action': ['RNAi therapeutic'], 'target': ['PCSK9'], 'indication': ['hypercholesterolemia'], 'preclinical_data': [], 'clinical_trials': ['Completed a Phase I clinical trial', 'Phase 1 clinical trial completed'], 'upcoming_milestones': ['Initiation of ALN-PCSsc Phase 1 clinical trial', 'Payments upon achievement of specified clinical development, regulatory approval, and commercialization milestones totaling up to $180.0 million'], 'references': [], 'aliases': []}, 'ALN-RSV01': {'target': ['respiratory syncytial virus (RSV)'], 'indication': ['RSV infection', 'respiratory syncytial virus infection'], 'preclinical_data': [], 'clinical_trials': ['Phase 1 clinical trial completed'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-RSV02': {'indication': ['pediatric patients'], 'preclinical_data': [], 'clinical_trials': ['Development on hold as of December 2010'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'ALN-TTR': {'target': ['transthyretin (TTR)'], 'indication': ['ATTR amyloidosis'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:18:24.218+0000] {local_task_job_runner.py:346} WARNING - State of this instance has been externally set to success. Terminating instance.
[2025-05-13T17:18:24.953+0000] {local_task_job_runner.py:245} INFO - ::endgroup::
[2025-05-13T17:18:25.305+0000] {process_utils.py:132} INFO - Sending 15 to group 1092. PIDs of all processes in the group: [1092]
[2025-05-13T17:18:25.334+0000] {process_utils.py:87} INFO - Sending the signal 15 to group 1092
[2025-05-13T17:18:25.366+0000] {taskinstance.py:3093} ERROR - Received SIGTERM. Terminating subprocesses.
[2025-05-13T17:18:30.059+0000] {taskinstance.py:340} INFO - ::group::Post task execution logs
[2025-05-13T17:18:32.146+0000] {process_utils.py:80} INFO - Process psutil.Process(pid=1092, status='terminated', exitcode=0, started='17:13:57') (1092) terminated with exit code 0
[2025-05-13T17:18:33.026+0000] {standard_task_runner.py:217} INFO - Process not found (most likely exited), stop collecting metrics
